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Abstract
Neutron capture therapy (NCT) is a form of cancer treatment that com-
bines neutron irradiation and the preferential loading of high concentra-
tion of neutron absorber (generally stable isotope), where the secondary
particles produced after neutron capture reaction deposit most of their
dose locally in target cancer cells, sparing the surrounding normal tissues.
Boron and gadolinium are two of few elements taken into consideration
as NCT agent due to their high neutron cross section and the character-
istics of secondary particles they produce after neutron capture reaction.
Even though currently used compound in clinical trials is boron-based
compound, investigations of gadolinium as NCT agent have been carried
out by many researchers interested in several advantages that gadolinium
offers.
Current clinical trials and experimental investigation of boron and gadolin-
ium as NCT agent have shown promising results for the application of this
therapy modality in cancer treatment. On top of that, recent development
of accelerator-based neutron source for a more hospital-friendly install-
ment has been encouraging more researchers to work on the optimization
of NCT treatment toward a wider application in radiotherapy.
In this thesis we evaluated the feasibility of gadolinium-based nanopar-
ticles for as agent by performing neutron irradiation to colon-26 tumor-
bearing mouse injected intravenously by gadolinium-based compound as
an effort to investigate the effectivity of cancer cells killing after NCT
treatment. Significant tumor growth suppression was observed for mice
group after neutron irradiation, indicating its effectivity in treating surface-
tumor. However, we observed significant toxicity in irradiated gadolinium-
platinum nanomicelles-injected group, suggesting that further investiga-
tion might be necessary to obtain the feasible optimization on combined
effect of radiochemotherapy.
Early stage of dose deposition investigation was also performed in this
study, aimed as an early stage before going into real calculation of dose
deposition for both boron and gadolinium based NCT. Investigation of
possible neutron depression effect was also preformed by setting up high
neutron agent concentration on simple cylindrical phantom as well as the
assessment of combined effect feasibility evaluation was also carried out
for the two compounds. Nevertheless, since the result of dose calculation
in current study is still a preliminary investigation, we can not come into
conclusion yet before performing further advanced calculation especially
the necessary to perform microdosimetry of dose deposition from very
short range secondary particles such as Auger and Coster-Kronig electrons
produced after GdNCR.
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Chapter 1
Introduction
1.1 Research Background and Motivation
Glioblastoma multiforme is one type of brain cancer, which is the most aggressive
diffuse glioma of astrocytic lineage and is classified into grade 4 based on WHO clas-
sification [1, 2]. With the average incidence rate of 3.19/100,000 population, median
survival of 15 months, and median age of diagnosis is 64 years, GBM remains an in-
curable disease [3]. The incidence and mortality are almost equal, indicating the fatal
outcome of this brain malignancy, and the need for new therapeutic approaches. Al-
though molecular biology-based therapeutic approaches are the major focus of current
clinical research efforts, a more immediate impact might be obtained by developing a
safe radiation dose-escalation strategy [4], and NCT represents such a novel approach.
Neutron capture therapy is a form of cancer treatment that combines neutron
irradiation and the preferential loading of target tissues or cells with particular com-
pounds [5]. In NCT, neutron beam is applied to the region of interest where the target
tissue contains a relatively high concentration of neutron absorber (generally stable
isotope) compounds compared to the surrounding normal tissues. Reaction between
these compounds with neutron creates secondary products that deposit most of their
dose locally, sparing the surrounding normal tissues as illustrated in Fig 1.1.
Thermal neutrons are preferable in NCT treatment, considering that slow neutrons
generally spend more time around a nucleus and are more likely to be captured. To
ensure maximum cell damage on target tissue, the neutron absorber nuclides used as
NCT agent need to have very high abilities to absorb thermal neutron (e.g. boron and
gadolinium) compared to other elements present in bulk of biological tissues shown
Table 1.1 to compensate the high percentage of those elements in tissue.
1
Normal
Cell
Cancer
Cell
Thermal Neutron
Cancer cells ionization by secondary 
particles after neutron capture reaction 
Figure 1.1: Illustration of cancer cells killing by neutron capture threrapy
Table 1.1: Thermal neutron cross section (σth)of the elements commonly present in
biological tissues [6]
Isotope σth (barn)
Weight (%)
in biological tissues
1H 0.333 10.00
12C 0.0035 18.00
14N 1.83 3.00
16O 0.00019 65.00
23Na 0.43 0.11
24Mg 0.0053 0.04
31P 0.18 1.16
32S 0.53 0.20
35Cl 32.68 0.16
39K 2.1 0.20
40Ca 0.4 2.01
56Fe 2.57 0.01
Note. 1 barn = 10−24cm2.
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Commonly used NCT agent in clinical trials is the isotope 10B, which splits into
high linear energy transfer α particle and 7Li nucleus upon neutron absorption. Alpha
particle and lithium ion emitted by the boron neutron capture reaction (BNCR) have
combined path length of approximately one cell diameter i.e. about 12 microns, which
theoretically limiting the radziation effect to those tumour cells that have taken up
a sufficient amount of 10B. However, this short flight range of alpha particles and
recoil lithium released after BNCR might also bring an inherent problem that it is
necessary to deposit boron homogenously intracellularly to destroy the cell.
Gadolinium-157 is another isotope under investigation as an alternative or com-
plimentary to boron in NCT. The use of gadolinium as NCT agent has been getting
attention because of its highest neutron cross section (255,000 barns) which is around
66 times larger compared to boron-10 thermal neutron cross section. The advantage
of gadolinium’s higher neutron cross section is that the same number of neutron cap-
ture reactions with 10B, can be produced with lower neutron fluence. Gadolinium
neutron capture reaction (GdNCR) also produces γ-rays, internal conversion elec-
trons, X-rays and Auger electrons with total kinetic energy about 3 times of that
produced by boron in BNCR. Gadolinium neutron capture reaction results in release
of gamma rays which is considered as a drawback as well as favorable characteristic,
because it might cause ionizing effect to outer normal tissue while at the same time
providing the advantage that the location of the element is not critical with regard
to target cell due to their longer flight ranges. Gadolinium neutron capture reaction
also produces a series of low-energy conversion and Auger electrons, which are high
linear energy transfer (LET) secondary particles effective in breaking DNA double
strand.
Besides boron and gadolinium, some other nuclides besides boron with high neu-
tron cross section, such as 6Li and 235U were initially also considered as NCT agent
(Table 1.2) [7, 8, 9]. However, ionic Li+ is mentioned to be easily dispersed thorogh-
out the body, while 235U has its inherent toxicity and radioactivity that finally they
were not further investigated. Nevertheless, NCT has been showing encouraging re-
sults on several clinical trials and animal experiments, not only on the glioblastoma
multiforme, as its first main target cancer type, but also on different types of cancer,
which has motivated a lot of research groups in working on the optimization of this
therapy modality.
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Table 1.2: Thermal neutron cross section (σth) of several nuclides considered to be
NCT agent [7, 8, 9]
Isotope Neutron capturereaction σth (barn)
3H (n,p) 5333
6Li (n,α) 941
10B (n,α) 3838
113Cd (n,γ) 20600
135Xe* (n,γ) 2720000
147Sm (n,γ) 40140
151Eu (n,γ) 9200
155Gd (n,γ) 60900
157Gd (n,γ) 255000
174Hf (n,γ) 561
199Hg (n,γ) 2150
235U* (n,f) 681
241Pu* (n,f) 1380
242Am* (n,f) 8000
Note: 1 barn = 10−24cm2. * Radioactive.
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1.2 Objective and Contributions of Thesis
The main purpose of this thesis is to carry out a thorough study of nanoparticles-
based neutron capture therapy, covering in vivo evaluation of two nanoparticles-based
gadolinium compounds as NCT agent, as well as an early stage calculation of dose
deposition to compare both boron neutron capture therapy (BNCT) and gadolinium
neutron capture therapy (GdNCT) and to evaluate the possibility of combining the
two compounds in NCT treatment.
In this work, in vivo evaluation for GdNCT was performed on colon-26 tumor-
bearing mice irradiated at nuclear reactor facility of Kyoto University Research Re-
actor Institute. Biodistribution of gadolinium-based drug compounds were observed
to decide the optimum time after compound administration to perform neutron irra-
diation of NCT procedures and antitumor effectivity was evaluated within one month
after NCT treatment. Preliminary investigation of NCT dose calculation was per-
formed by using PHITS (Particle and Heavy Ion Transport code System) calculation
method, as an independet approach for evaluating energy deposition for each of BNCT
and GdNCT as well as their combined effect.
1.3 Outline of Thesis
Chapter 1 in this thesis gives brief introduction of NCT as the research backround
and motivation, then outline the contributions of current works.
Chapter 2 will cover the basic principles of neutron capture therapy, starting from
the history of NCT itself; describe the current status of research fields in NCT, which
includes description of the mechanism for both BNCT and GdNCT; mention several
previous clinical trials and experimental results during long history of NCT; present
current development on neutron source and treatment planning for NCT; and finally,
discuss NCT prospects in the future will to give broader view of what lies ahead in
this field.
Chapter 3 will discuss about drug delivery system (DDS) in general, as well as its
important role in neutron capture therapy. Introductory description on the applica-
tion of nanoparticles as drug carrier in NCT, which is the main target of this work,
will also be given in more detail, together with several related works for both BNCT
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and GdNCT.
Chapter 4 will give the description of The Heavy Water Neutron Irradiation Facil-
ity of the Kyoto University Research Reactor (KUR-HWNIF) as neutron source for
GdNCT trial in current work. The characteristics of this reactor, which has been used
for many cases of NCT clinical trials, will also be outlined to give a brief overview of
the facility.
Chapter 5 will describe about the continued work of gadolinium-platinum na-
nomicelles evaluation compound as NCT agent. Nanomicelles preparation as well as
experimental methodology will be elaborated in more detail, and the results of anti-
tumor effectivity evaluation will be discussed in this chapter.
Chapter 6 will cover detail explanation of experimental results on evaluation of Gd-
DTPA/CaP nanoparticles as NCT agent. Advantages of calcium phosphate nanopar-
ticles itself will first be presented as the background of drug carrier choice. Single
and multiple injections of drug compund were performed for this gadolinium drug
carrier to investigate the effect of GdNCT on tumor site with different concentration
of gadolinium. The results will be presented and discussed as the evaluation of its
feasibility as GdNCT agent.
Chapter 7 will be the part in which preliminary study of dose deposition calcula-
tion in NCT will be presented. This chapter will give description about the simulation
system used for the calculation, simple phantoms designed in the calculation, as well
as description for the calculation setup. Simulation results will be discussed to obtain
preliminary understanding on energy deposition for both BNCT and GdNCT.
Chapter 8 will finally give concluding remarks about current research and sugges-
tions for future work.
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Chapter 2
General Introduction of Neutron
Capture Therapy
Neutron capture therapy (NCT) is one non-invasive cancer therapy approach, where
secondary particles produced after neutron capture reaction are utilized to ionize and
kill the cancer cells. In NCT, a stable, non-toxic, and non-radioactive nuclide is first
delivered and preferably accumulated into tumor cells, and then a neutron beam is
narrowly exposed to the target site. Based on the interaction of the nuclide and the
neutron beam, localized cytotoxic radiations are emitted to kill the tumor cells [10].
2.1 History of Neutron Capture Therapy
Soon after the discovery of neutron by Chadwick in 1932, the basic idea of binary
concept for cancer treatment with neutron capture therapy was introduced by Gordon
L. Locher in 1936 [5] : "In particular, there exist the possibility of introducing small
quantities of a strong neutron absorber into the regions where it is desired to liberate
ionization energy (a simple illustration would be the injection of a soluble, non-toxic
compound of boron, lithium, gadolinium or gold into a superficial cancer, followed by
bombardment with slow neutrons)". Since then, NCT has been through continuous
advancement in different fields of study including dedicated neutron beam facilities,
intense drug development, detection and imaging, computer-assisted dosimetry as
well as treatment planning software, as well as radiation oncology field.
The first experiment on boron neutron capture therapy (BNCT) was reported by
Kruger in 1940 [11], where he performed in vitro experiment with boric acid followed
by neutron irradiation and reported observation of lower transplantation efficiency
compared to controls. This was then followed by an in vivo experiment of NCT
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efficiency evaluation with the injection of boric acid on mouse sarcoma reported by
Zahl et al., [12]. After these reports, the treatment of brain tumors by NCT was then
proposed [13], in which the work also considered lithium together with boron as NCT
agent, as well as description on various agencies for localizing both compounds.
Following this result, the first clinical application of BNCT in human was per-
formed on 1951 in USA, where 10 patients with malignant glioma were treated at
the Brookhaven Graphite Research Reactor [14, 15, 16, 17]. It was reported that a
short-time improvement of the clinical situation was observed in nine of the ten cases.
The median survival of the patients in this first series was comparable to standard
therapy. However, improvement of clinical situation was short and all patients died of
their progressive disease. Unfortunately, significant survival prolongation could not
be achieved on several BNCT trials after this first clinical application. Some severe
side effects such as acute brain edema and perivascular fibrosis but especially the
appearance of brain necroses were even observed within a few months on the patients
treated at the reactor of the Massachusetts Institute of Technology after injection of
10B-enriched 4-carboxlyphenyl boronic acid [18, 19]. The unfavorable results of these
BNCT trials lead to discontinuation of NCT research in the USA for three decades.
The poor localization of boronated compound in tumor site was mentioned be one of
the possible causes of these discouraging results. Underestimation of dose contribu-
tion from fast neutron and photon contamination is also one of the aspects need to
be considered carefully.
Hiroshi Hatanaka brought NCT to Japan after his 2-year fellowship in Sweet’s
laboratory at the Massachusetts General Hospital, where the group there were work-
ing with BSH, which had been developed as a boron delivery agent by Soloway at the
Massachusetts General Hospital [20]. Hatanaka then resumed the BNCT clinical trials
in Japan, with the procedures of prior tumor excision as an intraoperative radiother-
apy before BSH injection and neutron irradiation. He reported encouraging results,
where 58% of a small group with selected patients suffering from malignant glioma
grades 3 and 4 achieved 5 years survival rate [21]. These promising results presented
by Hatanaka had then stimulated new efforts on BNCT clinical trials worldwide.
As also described in previous chapter, some other nuclides with high neutron cross
section were initially also considered as NCT agent. However, few of the unfavorable
inherent characteristics from those elements have halted further investigation of their
feasibility. Even gadolinium was at first precluded from the use for NCT because of
the high toxicity of its non-complexed inorganic salts. GdNCT itself was then revisited
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around late 1980s after the development of gadolinium-labeled MRI contrast agents
[22, 23].
2.2 Current Status of Neutron Capture Therapy
2.2.1 Boron Neutron Capture Therapy (BNCT)
Theoretically, BNCT provides a way to selectively destroy malignant cells and spare
normal cells. It is based on the nuclear capture and fission reactions that occur
when boron-10 (10B), which is a nonradioactive isotope of natural elemental boron,
is irradiated with low energy thermal neutrons to yield high linear energy transfer
(LET) alpha particles (4He) and recoiling lithium-7 (7Li) nuclei, with combined path
length of about one cell diameter, making it possible to optimize localization of cells
killing effect.
2.2.1.1 Properties of Boron as NCT Agent
Natural boron has two stable isotopes, which are 10B and 11B, with a natural abun-
dance of about 20 and 80%, respectively. Impure form of boron was first isolated by
Davy, Gay-Lussac, and Thénard in 1808 accomplished through the reaction of boric
acid with potassium. However, only in 1892 that a quite pure form of boron was ob-
tained by Moissan, who prepared elemental boron by the reduction of B2O3 with Mg.
In the past century, high purity boron was finally obtained. Boron has many similar-
ities with carbon and silicon. The main features that influence the chemical behavior
of boron are its small size, high ionization energy, and electronegativity that is close
to that of C and H (and Si), leading to an unusual ability to form covalent bonds
[24]. This feature affect its chemistry and is the main reason for the choice of boron
in medicinal chemistry, together with its large cross-section for neutron capture. It
is also possible to easily incorporate boron atoms in organic compounds.
The boron neutron capture reaction, 10B(n,α)7Li, was first characterized in 1935
and can be described by two parallel nuclear fission processes that take place upon
absorption of a thermalized neutron [25]. The excited 11B nucleus splits and produc-
ses two high energy ions, 4He2+ and 7Li3+ as described in Fig. 2.1, with the range of
approximately 9 and 5 µm respectively. Combined path length of these particles is
about the same size of one cell diameter, which makes it possible to localize irradia-
tion effect into target cells where boron compound is accumulated. Both of 4He2+ and
7Li3+ are high linear energy transfer (LET) particles; 1.47 for alpha particle and 0.84
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Figure 2.1: Schematic drawing for thermal neutron capture reaction of 10B(n,α)7Li
(adapted from [6]).
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Figure 2.2: Chemical structure of currently used BNCT agents: (A) Boronopheny-
lalanine (BPA). (B) Mercaptoundecahydrododecaborate (BSH). [6]
MeV for lithium recoil, making them efficient at localizing the cancer cell killing in
which the neutron capture reaction took place. However, the short range of these sec-
ondary particles may not reach the nuclei of some nearby cells, which might increase
the possibility of cancer recurrent [26]. Therefore, compared to secondary particles
with lower LET, the celullar range of alpha and lithium particles makes it necessary
to achieve homogenous delivery of 10B atom to every tumor cell nucleus to ensure the
desired therapeutic effect of BNCT.
2.2.1.2 Boron Delivery Agents
The only two BNCT agents currently in use for clinical trials are dihydroxyboryl
derivative of phenylalanine, referred to as boronophenylalanine or "BPA", and mer-
captoundecahydrododecaborate or "BSH" (Na2[B12H11SH]), with the chemical struc-
ture as shown in Fig. 2.2. BSH was used in the 1960s by Hiroshi Hatanaka as BNCT
agent for high grade gliomas [27], while BPA was first clinically used in 1988 by
Mishima on BNCT treatment of patients with cutaneous malignant melanomas [28].
BSH has the characteristics that it cannot pass through the BBB (Blood Brain
Barrier) effect. Since BBB of tumor cells are damaged, BSH is able to accumulate
in tumor cells without being taken up into normal brain cells. BSH also has poor
membrane permeability and low accumulation in tumor cells. Furthermore, because
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of its dependency on selective barrier such as the BBB in brain, it serves benefit
quite limited to malignant glioma [29, 30]. While the other boron delivery agent,
BPA, is capable of accumulating selectively in malignant melanoma because of its
chemical structure, which resembles tyrosine and DOPA (dihydroxy-phenylalanine),
the precursor of melanin metabolism. Moreover, BPA is also an amino acid analogue
hence it is taken up by the cells that amino acid metabolism is active and may pass
through the BBB. BPA is by character difficult to be dissolved in saline, but by
complexation with fructose it is possible to increase its solubility, which makes it
soluble at neutral pH. Therefore, BPA-fructose has become more commonly used as
BNCT agent for tumors. However, if compared to BSH, the BPA’s characteristics
of being capable on passing through BBB makes it unfavorable for treating brain
tumor, since BPA has the possibility to also accumulate into normal brain tissue.
Nevertheless, several results have been reported that boron accumulation in brain
tumor cells could be enhanced by combining each advantageous characteristics of
BPA and BSH [31].
Derivatives of BSH and BPA, other boron-containing amino acids, and boron
clusters have been synthesized in order to develop new low and high molecular boron
agent. One of the reason amino acids are employed for boron carrier is because they
have the tendency of selective accumulation in tumor cells due to increased amino
acid transport across plasma membranes on rapidly growing malignant cells, where
amino acids could be used for protein synthesis. Tumor cells might also overexpress to
specific peptide receptors, therefore, utilization of corresponding amino acids might
increase the possibilty of boron compound accumulation in tumor site [32]. Some
results on boronated amino acids reported recently, containing one or more boron
clustres in order to deliver higher concentration of boron to target tumor. Unnatural
boronated cyclic amino acids have also shown promising results as BNCT agent [33,
34] because of its higher metabolic stability compared with the natural ones. Recent
results reported by Kabalka et al., [35] have shown superior tumor selectivity of
boronated amino acids for both in vitro and in vivo.
Besides independet application of BPA and BSH, clinical trial on combined use
of these two BNCT agents has been reported by Miyatake for the case of GBM by
utilizing characteristic of each compound and expected different subpopulations in
tumor cells [36]. This combined use of two boron compounds was performed based
on experimental data showing different uptake characteristics of tumor cells depending
on the cell-cycle.
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In general, boron carriers has been through development in two directions: small
boron molecules and boron-conjugated biological complexes. Eventhough there have
been several studies reporting on the development of new boron compounds or carriers
of old compounds, the difficulty of translating many this experimental data into
clinical trial has been one of the reasons of the lack improvement in this part of
BNCT aspect. Because of the long and costly procedure necessary for the certification
of a new boron compounds to be achieved, boron-conjugated biological complexes
approach has become one of the recent trends to achieve high accumulation of 10B in
tumor tissues [37].
2.2.1.3 Clinical Trials of BNCT
Previously described two 10B-based compounds (BSH and BPA) have been used for
clinical trial in several NCT facilities in the world and has been showing promising
therapy results for patient with difficult to treat cancer type [38]. It was at first
aimed to treat brain cancer such as glioblastoma multiforme [39, 40, 41], but also is
currently being extended to the treatment of head and neck cancer [42, 43, 44], liver
[45, 46] and also melanoma [47, 48].
The first BNCT clinical trials in United States were performed using sodiom
tetraborate (borax), sodium pentaborate, p-carboxyphenylboronic acid, or sodium
decahydrodecaborate (Na2[B12H11SH]) utilizing thermal neutron source as its neu-
tron beam (cari reference nya). Later on 1990s, clinical trials in United States were
it was then resumed with BPA as its main boron delivery agent [41, 49, 50, 51],
and the patients were irradiated with higher enery epithermal neutron beam after
consideration of its deeper tissue-penetrating properties.
Hatanaka and Nakagawa in Japan performed pioneering BNCT trials using BSH as
the boron delivery agent with thermal range neutron beam [52, 53]. Afterward, several
clinical teams in Japan have carried out BNCT studies by using either BPA alone or in
combination with BSH, mainly on patients with glioblastoma [54, 55, 56, 57]. Later in
2001, Kato and his co-workers iniatiated BNCT trials on patients with recurrent head
and neck cancers. These patients had failed all other treatments before finally treated
with BNCT at Kyoto University Research Reactor Institute (KURRI) [58]. Promising
results were reported on 5 out of 6 cases of recurrent head and neck cancers treated
in the trials, even for a huge or far advanced head and neck malignancies (HNM). A
total of 42 times BNCT treatment for 26 patients have been performed since then by
the group reporting 1-72 months (mean 13.6 months) survival periods after BNCT.
They are capbale of ascertaining the effectiveness of BNCT for 22 out of 26 patients
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with advanced or recurrent HNM for which there were no other treatment options
[59, 60]. A more detail review on current status of BNCT of high grade gliomas and
head and neck cancer has been recently reported by Barth and co-workers [61].
Many research groups in Europe have also been working thoroughly on NCT,
with the group in Finland has carried one of the most intensive BNCT clinical tri-
als. BNCT research in Finland has been actively performed since 1992 [40, 62, 44].
FiR1 research reactor was constructed between 1993 to 1997 as treatment facility and
started to use for clinical trials on 1999 [63], and the facility was mentioned to be
capable of treating patient regularly on a weekly basis [64]. Several developments
on optimization of neutron source, dose calculation and treatment planning, boron
imaging up into molecular level, as well as diffusion imaging to detect BNCT effect
in patients were performed by BNCT group in Finland to promote full potential of
BNCT [65]. Unfortunately, the treatments in FiR1 facility was unavoidably termi-
nated in 2012.
Some other clinical trials in Europe is the one conducted in Petten (performed by
European Organization for Research and Treatment of Cancer) and Czech Republic,
using BSH either alone or in combination with BPA on patients with GBM to investi-
gate the toxicity of i.v. administration on BSH and the maximum tolarated radiation
dose [66, 67, 68]. Clinical studies were also performed in Sweden with higher total
amount of BPA infused for over 6 hours to the patient undertaking the treatment
[69]. This higher dose and longer infusion time was reported to be tolerated by 29
patients enrolled in the study [39, 70].
Besides those clinical trials in US, Japan, and Europe, BNCT group in Taiwan has
also presented their preliminary clinical trial results on patients with locally recurrent
head and neck cancer, where they observed shrinkage of tumor with tolerable early
toxicities after treatment [71].
2.2.2 Gadolinium Neutron Capture Therapy (GdNCT)
Celullar range of alpha and lithium particles produced after BNCR as described at
the beginning section of this chapter, makes it necessary to achieve homogenous and
intracellular delivery of 10B atom to every tumor cell nucleus to ensure killing effect
and minimize possibility of recurrence. Gadolinium as an alternative of boron for
NCT agent is considered to be capable of compensating the difficulty on homogenous
element distribution with its longer range secondary particles produced after neutron
capture reaction.
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GdNCT was first formulated in the in the 1980s [72, 73]. However, its development
has suffered due to lack of appropriate Gd-containing tumor-selective agents [74]. Its
clinical application has been rather limited because of the difficulty in retaining a
sufficient amount of Gd in tumors (50-200 µg of Gd/g wet tumor tissues) during the
neutron irradiation [26].
The use of gadolinium as NCT agent has been getting attention because of its
highest neutron cross section (255,000 barns) which is around 66 times larger com-
pared to boron thermal neutron cross section. The advantage of gadolinium higher
neutron cross section is that the same number of neutron capture reactions with
10B, can be produced with significantly lower neutron fluence. Thus, it is possible
to reduce neutron dose received by surrounding normal tissue by using 157Gd com-
pound. The spectrum of the secondary particles emitted by gadolinium is complex,
and spreads out a broad region of dose delivery, thus limiting the selectivity of the
therapy. The photons emitted in the (n,γ) reactions interact with the tissues but
deposit energy over a longer path length than the boron reaction products. This is
the main drawback of GdNCT. However, if 157Gd uptake is limited to tumor bulk,
having a size of the order of some cm3 by volume, then an additional effect, in the
increasing of tumor dose in the attenuation of the capture photon yield, will be added
[75]. These properties of GdNCT can also increase the possibility of killing tumor
cells even when Gd is outside the tumor cells, thus eliminating the requirement of
intracellular delivery of gadolinium [76].
GdNCT is recently rekindled mainly based on the action of its high linear energy
transfer (LET) Auger and IC electrons generated by 157Gd after neutron capture.
Dose contribution of gadolinium neutron capture reaction (GdNCR) short-range prod-
ucts such as Auger electro emission has often been neglected because it was assumed
that Gd compounds remained extracellular and could not reach the cell nucleus.
However, De Stasio et al., [76] showed that Gd-DTPA not only penetrates the plasma
membrane of the cells but accumulates at higher concentration in the nucleus than
in the cytoplasm.
2.2.2.1 Properties of Gadolinium as NCT Agent
Gadolinium, a rare earth lanthanide, was discovered in 1886 by Charles Marignac,
who named it after the Finnish chemist, Johan Gadolin. The 40th most abundant
element in the earth’s crust, gadolinium is a bright, silver, ferromagnetic metal, and
is usually found in the mineral monazite [77]. Investigations of the nuclear properties
of gadolinium began shortly after the discovery of the neutron. In fact, 157Gd has the
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Table 2.1: Stable gadolinium isotopes. The natural abundance and neutron cross
sections of gadolinium isotopes with atomic weights from 152 to 160 [77].
Stable Isotope 152Gd 154Gd 155Gd 156Gd 157Gd 158Gd 160Gd
Natural abundance (%) 0.20 2.18 14.80 20.47 15.65 24.84 21.86
Thermal neutron
absorption, σth (barns)
700 60 61000 2 255000 2.4 1
highest thermal neutron cross section of any isotope of any element. This high cross
section is the reason why gadolinium has been investigated for many nuclear physics
applications, ranging from nuclear control rod absorbing material to the medical
neutron capture therapy research.
There are seven stable isotopes of gadolinium and eight radioisotopes with half-
lives longer than one day. Table 2.1. lists the gadolinium isotopes with atomic weight
from 152 to 160, their natural abundance and neutron cross section [77]. Of these
stable gadolinium isotopes, the candidates for NCT are those with very high neutron
capture cross sections. It is shown that 157Gd has the highest neutron cross section
and significant natural abundance compared to the other isotopes. This high neutron
cross property of gadolinium, which is approximately 66 times that of 10B, can help
to shorten the irradiation time and is expected to improve patient’s quality of life
after NCT treatment.
Schematic drawing of a thermal neutron capture reaction of 157Gd is shown in
Fig. 2.3. 157Gd atom, which has 15.65% natural abundant ratio, releases Auger
electron, internal conversion (IC) electron, γ rays and X rays by a thermal neutron
capture reaction. Among these, the most biologically relevant for cancer cells killing
are the high LET Auger and IC electrons with an average LET of 0.3 MeV/µm. By
comparison, in boron neutron capture therapy the average LET is 0.2 MeV/µm for
both Li and alpha particles [4].
Mass-and charge-carrying Auger electrons are highly ionizing over a short range.
The longest radiation length is on the order of tens of nanometers for most energetic
electrons. Most favorably for GdNCT, Auger electrons may induce double-strand
damage if gadolinium is in the proximity of DNA [73]; which requires gadolinium com-
pound to be accumulated intranuclearly to ensure dose enhancement due to double-
strand damage inside cell nucleus. When Auger Coster-Kronig electron is emitted, it
most likely will interact with a water molecule within radius of a few nanometers pro-
ducing hydroxyl radical, which in turn locally propagates the oxidativfe damage [72],
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Figure 2.3: Schematic drawing for thermal neutron capture reaction of
157Gd(n,γ)158Gd (adapted from [6]).
and it has been reported that lethal double-strand DNA breaks occur in proportion
to the extent of the radiation-induced oxidative damage [4].
Several gadolinium-based compound are already commonly used as MRI contrast
agent, which makes it possible to integrate radiotherapy and MRI diagnosis. This
would permit the simultaneous dynamic MRI monitoring of the gadolinium distribu-
tion levels prior to and during neutron irradiation for better treatment results. The
possibility of real-time observation of drug distribution will eventually increase the
accuracy of the treatment and enable to feedback the therapeutic efficacy at the ear-
lier stage and promptly adjust the treatment strategy [78]. Several Gd compounds
are known to target brain gliomas because of the BBB disruption in these tumors.
They are in fact used as tumor contrast-enhancing agents for MRI, a result of the
large magnetic moment of the Gd3+ ion.
2.2.2.2 Gadolinium Delivery Agents
Gadolinium ion (Gd3+) is known to be toxic and must be chemically stabilized by
chelation. Therefore, standard 157Gd-containing MRI contrast agents should be con-
sidered as the most realistic option for GdNCT agent. Their pharmacology has been
extensively studied and has already been approved for clinical use. The optimal 157Gd
concentration in tumors for GdNCT was reported to be 50-200 µg/g tumor tissues,
and less than 1,000 ppm since neutron fluence rapidly decrease in the deeply seated
tumor due to high absorption of neutron by Gd atoms [79]. Several MRI contrast
agent such as Gd-DTPA, Gd-DOTA, Gd-BOPTA, Gadoteridol and Gadobutrol have
been reported to be evaluated as the feasible GdNCT agents (described in the fol-
lowing subsection). Motexafin gadolinium, a redox-active tumor selective agent, has
also been considered to be utilized as GdNCT because of its characteristics of be-
ing capable in accumulating gadolinium into brain tumor and mostly to cell nuclei
[80, 81].
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In the past GdNCT trials, several MRI contrast agents were evaluated as gadolin-
ium compound for NCT, but it was a major problem that a sufficient quantity of
gadolinium could not be retained in tumor tissue during neutron irradiation after
compound injection [82] and most of gadolinium-based MRI contrast agents are re-
ported to have short blood circulation time and low specificity in tissue accumulation
[22]. Thus, effective drug delivery systems are needed in order to deliver sufficient
amount of Gd into tumors for the optimization of GdNCT. This has been more fo-
cused on for the optimization of GdNCT compared to the development of the new
gadoliniium-based compound besides the established MRI contrast agent.
2.2.2.3 Status of GdNCT Feasibility Evaluation
Studies on GdNCT have been limited to in vitro and in vivo experiments due to the
lack of efficient drug delivery system of gadolinium compound, and also because of
the longer range gamma rays it produces after neutron capture reaction. Neverthe-
less, quite a lot of reports have been presented suggesting promising applicatin of
gadolinium as NCT agent.
De Stasio and co-workers [4] have reported the promising results of Gd-DTPA and
Gd-DOTA accumulation by performing in vitro experiment using human glioblastoma
cell lines, as well as in vivo studies on C6 glioblastoma-bearing rats. It was found
that gadolinium is present in 54 and 85% of cell nuclei after single and double Gd-
DOTA injection, respectively. They also performed GBM resection on six GBM
patients, who had agreed for injection of Gd-DTPA 1-2 hours before tumor excision.
The results have shown that only 6.1% of cell nuclei contain Gd pixels detected
by MEPHISTO spectromicroscope [83] after single injection of Gd-DTPA. However,
the extrapolated experimental results of in vitro-in vivo correspondance indicated
the possibility of achieving 84% of gadolinium accumulation in tumor cell nuclei
after 72-hour continuous infusion. Theoritically, multiple administration and longer
exposure of Gd compound might lead to higher accumulation and prolonged retention
of gadolinium in target cells.
Our previous work on colon-26 tumor-bearing mice injected with gadoteridol-
encapsulated liposome has also shown significant tumor growth suppression of GdNCT
treated group compared to the non-treated group suggesting the effectivity of gadolin-
ium as NCT agent [84]. In vitro and In vivo evaluation results reported by Hofmann
and co-workers [85] have shown that the use of Gadobutrol MRI contrast agent re-
vealed therapeutic benefit with the neutral Gd complex after GdNCT treatment on
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melanoma cells and solid tumor. Khokhlov and co-workers have also presented en-
couraging results on in vivo experiment application of gadopentetate dimeglumine
as GdNCT agent on tumor-bearing rats [86]. Yasui and co-workers [87] have also
reported the effectivity of gadolinium neutron capture therapy in vitro on glioblas-
toma multiforme cells, where they observed significant enhancement of cell killing
on cells preloaded with Gd-DTPA and treated with neutron irradiation. Following
observation of no necrosis with high cancer cells killing effectivity after GdNCT was
reported in their experiment compared to other mice group treated with gamma, fast
neutrons, and modified enhanced thermal neutron beam [88].
Even though most of current evaluations on GdNCT is still limited to in vivo and
in vitro experiments, many types of cancer have been evaluated worldwide and the
results have been showing encouraging and promising therapy effectivitiy that this
investigation is worth to be advanced for optimization of NCT in the future, either
as an alternative to boron, or as a complimentary in the development of NCT agent.
2.2.3 Neutron Sources for NCT
The concept of NCT itself was actually formulated long before the establishment of
appropriate neutron sources. Early clinical trials for the treatment of high grade
gliomas in Brookhaven National Laboratory (BNL) and the Massachusetts Institute
of Technology (MIT) were conducted with beams of thermal neutrons and have ac-
tually revealed NCT effectivity in cance cells killing [14, 15, 17]. However, because of
the poor tissue penetration of thermal neutrons, clinical team in MIT/Harvard had
then performed open cranium irradiation to enhance neutron penetration and reduce
unwanted dose to the scalp. Since then, epithermal neutron beam has been more
preferable as neutron source for NCT especially to treat deep-seated tumor.
2.2.3.1 Reactor-based Neutron Source
Currently, neutron sources for NCT are still limited to nuclear reactors. Neutrons
derived from reactors are commonly classified according to their energies as thermal
(En < 0.5 eV), epithermal (0.5 eV < En < 10 keV), or fast (En >10 keV). The
neutrons, and gammas, emanating from the reactor, need to be moderated, filtered
and/or attenuated, such that the required beam intensity and average neutron energy
are within the requirements, which themselves can vary depending on the type of
tumours to be treated. However, because thermal neutrons have a limited depth of
penetration, it is recommended that an epithermal neutron beam is the most desirable
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beam with respect to having the greatest potential for the treatment of many tumour
types, sespecially deep-seated ones, because it loses energy and fall into the thermal
range as they penetrate tissue.
Several reactors with very good neutron beam quality have been developed and
used clinically for NCT trials. These include (a) MITR; (b) the clinical reactor at
Studsvik Medical AB in Sweden; (c) the FiR1 clinical reactor in Helsinki, Finland;
(d) R2-0 High Flux Reactor at Petten in the Netherlands; (e) LVR-15 reactor at the
Nuclear Research Institute in Rez, Czech Republic; (f) Kyoto University Research
reactor in Kumatori, Japan; (g) JRR4 at the Japan Atomic Energy Research Institute;
and (h) the RA-6 CNEA reactor in Bariloche, Argentina; (i) National Tshing Hua
University reactor (THOR) in Taiwan; (j) Low power reactor in a suburb of Beijing
in China [90, 91]. Unfortunately, some of these reactors are no longer open to treat
patients or under threat of closure
Two approaches have been used for the design of epithermal neutron irradiation
facilities at fission reactors. Major approach are direct use of core neutrons, where
more of such facility have been constructed for clinical use in America, Europe and
Asia. Another approach is the use of sub-critical array of fuel called fission converter,
initially proposed by Rief and co-workers [92], where fission neutrons are produced
oustide the reactore core from thermalised neutrons emanating from the reactor.
However, it is quite impossible to build a new reactor in the near future, especially
near medical facilities, due to recent environmental concern about nuclear activities
after the accident in Fukushima, Japan.
A total number of more than 1,000 BNCT clinical trials have been performed
worldwide. Looking at the encouraging results of BCNT clinical trials in several
nuclear reactor facilities (as described in previous subsection), it is expected that an
efficient and optimized neutron source incorporated with hospitals could be developed
in the near future in order to restart BNCT treatments in several countries where the
trials are currently being halted and to obtain further positive clinical trial results for
NCT to be approved and applied as common therapy modality.
2.2.3.2 Accelerator-based Neutron Source
Accelerator-based neutron source (ABNS) is a more attractive option for a compact
neutron source to be to be sited in hospitals, allowing for more effective but tech-
nically more complicated procedures to carry out NCT. Many efforts are currently
being performed to optimize neutron beam produced by ABNS. However, it is still a
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challenge to construct ABNS with a beam quality comparable with that of the nuclear
reactor, that provides a current of sufficient magnitude for clinical trials.
ABNS generally produce low intensity neutron fluxes compared to reactor sources
and this has been a problem for its implementation. An increase in neutron beam
intensity is crucial if ABNS are to be competitive with nuclear reactor sources for clin-
ical NCT. In those ABNSs developed for NCT treatment currently being developed
in some countries as an alternative of neutron sources for NCT, neutron is produced
from nuclear reaction induced by charged particles. Lithium and beryllium are two
of the elements to be considered as target material to be bombarded by charged
particles in ABNS system for NCT. Among various reactions to produce accelerator-
based neutrons, bombarding a 7Li target with protons is one of the efficient method
because high neutron yield in relatively low energy ranges. A sufficiently low accel-
erator current (10 mA) is required for producing a high intensity of reasonably low
energetic neutrons with the average energy of 0.4 MeV and maximum energy of 0.8
MeV [90, 65]. Such neutron beams with functional lithium targets and beam shaping
assemblies have been studied and developed at the University of Birmingham in the
UK [93], the Institute for Physics and Power Engineering in Obninsk Russia [94] and
the Atomic Energy Commission of Argentina in Buenos Aires [95], as well as the
group in Korea [96, 97, 98].
Due to lower and less widely distributed neutron source energies; ABNS poten-
tially can produce neutron beams with an energy distribution that is equal to or
better than that of a reactor. However, reactor derived neutrons can be well colli-
mated, while in contrast it might be difficult to achieve good collimation of ABNS
neutrons at reasonable proton beam currents. The necessity of good collimation for
the effective NCT treatment is another important and tough issue that may affect
usefulness of ABNS for NCT. Furthermore, since the beam position in ABNS system
is stationary, the patient needs to be directed and rotated in the treatment fields,
which have become one of the issue to be handled in optimizing the use of ABNS
in NCT treatment [99, 100]. Development of the ABNS for NCT is still facing few
challenging tasks; the necessity of high power accelerator to producing high-current
particle beam, the threshold and compensation in choosing appropriate target with
efficient heat removal system, and an optimized beam shaping assembly (BSA) to
reduce initial neutron energy produced by the system down to the optimal range for
NCT treatment [101].
The most recent ABNS facilities are those in Japan, especially the facility at Kyoto
University Research Institute, which has obtained approval by the Pharmaceutical
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and Medical Safety Bureau of the Japanese Ministry of Health, Labour, and Welfare.
They have started the clinical trial with the system constructed by Sumitomo Heavy
Industries [102]. In this ABNS facility, neutrons are produced by hitting beryllium
plate with proton beam from a 30 MeV cyclotron. Emitted neutrons are moderated
by lead, iron, aluminium and calcium fluoride. Peak neutron fluxes of 1.8 × 109
n/cm2/s at 20 mm from the surface with 1 mA proton beam have been measured in
phantoms.
Another recent project on ABNS in Japan is being developed by a group in Ibaraki
Prefecture, Japan. This project is a collaboration between University of Tsukuba,
High Energy Accelerator Research Organization (KEK), JAEA, Hokkaido University,
Ibaraki Prefecture and Mitsubishi Heavy Industry Co. (MHI). Different from the
ABNS system in KURRI, this team has selected beryllium as target material with
incident particel of 8 MeV proton beam. Calculation results have been reported to
achieve the goals of epithermal neutron flux (>2.0 × 109 n/cm2/s) at the beam port,
when average proton current is set to 10 mA. Accelerator facility has been installed
and a new Monte-Carlo based system treatment planning is currently under develop-
ment [103]. Few other projects of ABNS in Japan such as the one in Southern Tohoku
Research Institute for Neuroscience in collaboration with the facility in KURRI, and
also the project at National Cancer Center, which are providing promising future
wider application of NCT in patient treatment.
A more detail discussion on possible charged-particle-induced nuclear reactions is
presented by Kreiner [104], covering the characteristics of produced neutron beam
along with development of ABNS facilities worldwide, as well as several advatages
that ABNS offer compared to currently employed nuclear reactor [105, 91]. The
optimization of ABNS for NCT treatment would eventually give a big impact into the
socialization and familiarization of this therapy modality for a more patient-friendly
facility in the future.
2.2.4 Other Developments
Besides those aspcets, which have been previously discussed about the developments
of drug delivery and neutron source, other development such as detection and imaging
as well as dosimetry and treatment planning for NCT also play important role in the
optimization of NCT effectivity.
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2.2.4.1 Detection and Imaging
As also mentioned in the subsection of Drug Delivery System, high tumor accumula-
tion of boron or gadolinium along with high concentration ratio compared to blood
and normal tissue, is necessary to ensure localization of radiation effect into tumor
target. Therefore, detection of boron or gadolinium compound during NCT treat-
ment is a crucial factor in order to fully comprehend cancer cells killing effect during
treatment. It is necessary to determine biodistribution of administrated drug com-
pound in tumor site or normal tissue of patient’s body up to the subcellular level, its
molecular accumulation as well as the transport and circulation of drug compound in
the body.
Detection and imaging methods for NCT should be capable of quantifying bulk
concentration of NCT agent as well as its spatial distribution at macroscopic and
microscopic level. Non-invasive methods are preferable to allow for in vivo measure-
ment, especially those with the capability to be performed during neutron irradiation,
has quick response and are capable of visualizing an online detection analysis of drug
distribution. However, most methods that have been developed up until now are
invasive and still face the difficulty for an online detection.
Prompt gamma-ray analysis (PGRA) is one of the fast method that is capable
of measuring the average concentration of element in samples and has been used for
many years in BNCT trials [106, 107, 108, 109]. Khokhlov and co-workers [110] have
reported the application of PGRA on both of boron and gadolinium in their MEPhI
neutron facility for pharmacokinetic studies and has proven that the system is capable
of measuring concentration of boron and gadolinium with satisfying detection limit
required for NCT treatment. Several reports on the development of detecting system
were also presented by several groups, especially those who work on semiconductor
detector for the application of BNCT SPECT [111, 112, 113, 114, 115, 116]. These
works are mostly focusing on the detection of 478 keV gamma ray produced after
BNCR (as shown in decay scheme of 11B in Fig. 2.4).
Development of detecting system for clarification of intra tumor distribution for
boron and gadolinium with micro-particle induced X-ray emission (PIXE) analysis
was also conducted by Endo and co-workers [117], followed by the work of Yamamoto
and co-workers [118] in which they demonstrated intra tumor visualization of gadolin-
ium distribution after administration of gadolinium containing fullerene, indicating
the feasibility of Micro-PIXE as imaging technique for NCT. Detection of charac-
teristic X-ray emission after GdNCR was also considered to be feasible method of
quantifying gadolinium biodistribution as continous work of the group from Canada
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Figure 2.4: Decay scheme of 11B after neutron capture reaction by 10B(adapted from
[124])
[119, 120, 121] by emphasizing on the detection of characteristics X-ray of energy as
shown in gadolinium decay scheme shown in Fig. 2.5. The detection limit was re-
ported to be better by around 30% compared to analysis without incorporating X-ray
signal.
Inductively Coupled Plasma-Atomic Emission Spectroscopy (ICP-AES) together
with ICP-MS (Inductively Coupled Plasma Mass Spectrometry) are two methods of
quantitative analysis in measuring element concentration in samples. ICP-MS is often
preferable over ICP-OES in determining boron concentration in samples because it has
higher sensitivity and lower detection limits. Compared to other methods, ICP-MS is
also capable of measuring isotopes of 10B and 11B simultaneously in one sample [123].
A more detail review on boron analysis and imaging has been reported elsewhere,
where it also includes autoradiography methods, laser post-ionization secondary neu-
tral mass spectrometry (laser-SNMS), ion trap mas spectrometry, as well ass nuclear
magnetic resonance (NMR), magnetic resonance imaging (MRI) and positron emis-
sion tomography (PET) [124].
2.2.4.2 Dosimetry and Treatment Planning System
Dosimetry and treatment planning for NCT demands a high technical quality of the
involved dose contributing components. The physical parameters involved are well
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known but interact in a rather complex way, requiring specialized software for the
dose estimation. calculation of the absorbed dose in a target organ is determined
by the sum of the doses of neutrons and secondary gamma, and the dose of primary
photons of the beam.
Compared to conventional radiotherapy, where usually only a single low-LET
dose component must be computed, the radiation field in NCT is a complex mixture
of high- and low-LET dose components with varying biological effectiveness that
depends on both the tissue and the chemical form of the neutron capture agent. The
spatial distribution of each dose component is different and depends on the tissue
composition as well as the neutron and photon fluence spectra.
Treatment planning system for NCT mostly rely on Monte Carlo simulations
because of the complex neutron transport. Dose calculation is conducted by inte-
grating neutron and photon flux against energy-dependent kerma coefficients during
neutron irradiation [49, 125]. In some planning systems, doses are computed on an
element-wise basis, while in others doses are calculated using kerma factors precom-
puted depends on the tissue composition. A more detail summary on NCT treatment
planning system is recently reported by Kumada and Kiger [126].
A lot of efforts have been carried out for the optimization of NCT dosimetry in-
volving both boron and gadolinium. A more established dosimetry and treatment
planning systems are currently available for BNCT compared to those for GdNCT.
However, the optimization and the attempt to perform an international dosimetry
exchange for BNCT has been conducted to enable future combination of clinical data
from different centers conducting BNCT trials [127, 128]. Several studies on micro-
dosimetry calculation have also been reported as an effort to optimize the estimation
of delivered dose during NCT treatment [129, 130, 131, 132]. Estimation of neu-
tron kerma in biological tissue containing boron and gadolinium was also reported by
Sheino and co-workers [133], where they performed calculation of neutron and photon
kerma during NCT and also presented comparison of calculated parameters of electron
and photon spectra after GdNCR between several previous reports [134, 135, 136]. A
more recent dosimetry calculation was reported by Enger and co-workers [137], where
they performed Monte Carlo simulation for neutron and photon absorbed dose on a
cell model with three scenarios of gadolinium accumulation.
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Figure 2.6: Comparison of neutron cross section between 10B and 157Gd [138, 139]
2.3 Comparison of BNCT and GdNCT
The neutron interaction characteristics are generally similar between 10B and 157Gd,
as shown by the comparsion of their total cross sections in Fig 2.6. As previously
mentioned, the higher neutron cross section of gadolinium bring about the advantage
that the same number of neutron capture reactions with 10B, can be produced with
significantly lower neutron fluence. Thus, it is theoritically possible to reduce neutron
dose received by surrounding normal tissue by using 157Gd compound. However, the
secondary particles it produces after capturing neutron are a mixture of prompt and
cascade-induced photons and electrons, which reduce the localization effect of cancer
cells kiling. GdNCR produces longer range gamma rays as plotted in Fig. 2.7.
Referring to the interaction range of photons in water as described in Table 2.2, it
is evident that the secondary particles of GdNCR (especially its gamma rays) might
deposit its energy up to few centimeters range and might affect surrounding normal
tissue, which is not desirable in cancer therapy. Nevertheless, there are positive
aspects associated with a lack of dose localization when considering non-uniform
drug uptake in the advanced and diverse tumor targeted with BNCT. If the uptake of
157Gd is isolated to a bulk tumor cluster in the order of few cm3, then an additional
effect will supplement the attenuation of the capture photons.
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Figure 2.7: Library representation of MCNP MISC5XS1 for spectrum of gamma
radiation after thermal neutron capture reaction of 157Gd [139, 141].
As illustrated in Fig. 2.8 [140], we can see the comparison of energy deposition
effect between high and low LET in cell. The characteristic of high LET radiation,
such as α particles, is that the ionizing effect is concentrated in a relatively small
number of dense tracks of limited range. Therefore, if the doses given is low, it is
quite a problem to ensure the effectivens of cell killing by ionization due to this single
track. While for low LET ionizing radiation, such as gamma rays or X-rays, the
energy deposited on cells is sparse and more distributed. For that reason, even low
doses of low LET might still result in cell killing effect although the dose is reduced.
Furthermore, by looking at the decay scheme of 158Gd in Fig. 2.5, there is also
the possibility of cancer cells killing effect from the DNA strand break caused by the
short range Auger and Koster-Cronig electrons as illustrated in Fig. 2.9. The most
commonly emitted electron energies after GdNCR have ranges that are many times
the dimensions of the average 10 µm of cell diameter. In water, 50 keV electrons
have a range of 42 µm and 100 keV electrons have a range of 140 µm [142, 143],
which would also add into the effectivity of GdNCT treatment. A brief summary of
comparison between BNCT and GdNCT is presented in Table 2.2.
A Feasibility evaluation of comparison and combination between gadolinium and
boron for NCT has been previously reported by Tokuuye and co-workers [147] and
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Table 2.2: Selected interaction range for photons in water [142]
Photon energy (keV) 1/µ (cm)
5 0.024
10 0.197
100 5.86
150 6.64
1000 14.1
2000 20.2
6000 36.2
Figure 2.8: Schematic representation of a cell nucleus irradiated with two electron
tracks from gamma-rays (low LET) or two α-particle tracks (high LET) [140], origi-
nally published by Goodhead [144].
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Figure 2.9: Illustration of radiation effect on DNA strand break [145].
Table 2.3: Characteristics Comparison of BNCT and GdNCT
BNCT GdNCT
Thermal neutron cross section 3,830 barns for 10B 255,000 barns for 157Gd
Average total kinetic energy
(Q-value) ≈ 2.33MeV ≈ 7.94MeV
Secondary particles range - 5.33 - 5.97µm for Li particle- 9.62 - 11.14µm for α particle
- 0.1 - 1µm for Auger electron
- 14 - 360µm for IC electron
- Up to few centimenters for
long range gamma raysµm for
IC electron
Approximated required neutron
fluence ≈ 10
13 - 1014n/cm2 ≈ 1011 - 1012n/cm2
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also by Matsumura and co-workers [146], where the results indicate varied additive
effects depending on gadolinium concentration and it was suggested that achieving
suitable concentrations of both gadolinium and boron in the tumor may increase their
therapeutic effect, but an excessive concentration may result in a negative therapeutic
effect. A computational assessment of improved cell-kill by gadolinium-supplemented
on boron neutron capture therapy was also previously reported by Culbertson and
Jevremovic [148], where they performed dosimetry calculation and quantified the
benefits and limitations of gadolinium-supplemented BNCT. Therefore, it is necessary
to carry out further investigation on combined effect of BNCT and GdNCT instead
of separate use only of these radiotherapy modalities.
2.4 Neutron Capture Therapy Prospects in the Fu-
ture
Collaboration between different disciplines from nuclear physics, medical doctors,
chemistry, radiation oncology, mathematics to treatment management, is crucial for
the success of neutron capture therapy. Interdisciplinary exchange between those sci-
entific communities will contribute much to the development of NCT treatment. A
well-developed hospital-based neutron source is also one of the important aspects to
optimize the application of neutron capture therapy itself. An easy-to-understand
socialization to public would also play an important role in the advancement of NCT.
With many parameters and variables to be considered and taken into account, de-
velopment of NCT has been quite challenging and rewarding that brings scientists
and researchers from different fields together, because the improvement of one aspect
could correlate to the others. A combination of boron and gadolinium in NCT as
well combination of NCT with other types of radiation therapy (e.g. proton therapy,
brachytherapy and synovectomy) would be more beneficial instead of exploiting each
of them as a single treatment.
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Chapter 3
Nanoparticles as Drug Delivery
System in NCT
As also remarked previously, one of the key factors for the success in NCT is to deliver
and maintain sufficient amount of NCT agent (e.g. boron and gadolinium) in tumor
tissues during neutron irradiation. Therefore, an efficient drug delivery system plays
a great role as a method or process of administering a pharmaceutical compound to
achieve a therapeutic effect in humans or animals. With drug delivery system, it
is possible to modify drug release profile, absorption, distribution, and elimination
for the benefit of improving drug efficacy and safety, as well as patient convenience.
This chapter will discuss in more detail about mechanism of drug delivery system and
describe more about the application of nanoparticles as drug carrier.
3.1 General Introduction of Drug Delivery System
Drug delivery system is a method or process of administering a pharmaceutical com-
pound to improve their accumulation in target site. It modifies drug release profile,
absorption, distribution, and elimination for the benefit of improving drug efficacy
and safety, as well as patient convenience. A drug delivery system (DDS) is most
often associated with particle carriers such as emulsion, liposome, and nanoparticles,
which are designed to optimize drug localization and drug-release in the target site
[149]. The biodegradable drug delivery systems have received considerable attention
as potent carrier for enhancing the objective effects and minimizing the side effects
in various therapies.
It is important to consider several parameters such as; route administration, prod-
uct stability, toxicity, and efficacy, to decide the appropriate drug delivery systems to
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get an optimum drug accumulation and an improved therapeutic efficacy. An efficient
drug carrier should be able to establish high tumor to normal tissue (T/N) and tu-
mor to blood (T/B) concentration ratio in order to deliver high radiation dose to the
tumor with tolerable dose to healthy tissue. Particulate carriers such as emulsion, li-
posome, and nanoparticles, have been of interest for drug delivery system considering
that they posses the characteristics necessary to enhance drug localization and allow
for a slow drug release from the delivery system in the target site [149]. A slow and
limited release should also slow down the diffusion of the drug compound out of the
tumors before and during the neutron irradiation. Administration route is also one of
the most important factors in biodistribution and pharmacokinetics of drugs carriers.
Previous study by Miyamoto and co-workers [150] had shown that intraperitoneal
(i.p.) route allows the injection of relatively large amount of gadolinium compound
and consequently delivers a large amount of gadolinium to the tumor via the systemic
circulation. However, even with i.p. injection, many factors affect the biodistribution
and pharmacokinetics of the drug carriers, including the absorption of these carriers
from the abdominal cavity and the localization of these carriers in the lymph nodes,
making the estimation of the in vivo fate of the drug carriers difficult [151].
3.1.1 Targeted Drug Delivery
Delivering drug into target area is generally divided into categories of "passive" and
"active" targeting. Passive targeting usually occurs to most of drug carriers by taking
advantage of the leaky vasculature around tumor area. It is known that the blood
vessels in some diseased tissues (e.g. at tumors and inflammation sites) are not well-
developed and rather leaky. Therefore, colloidal particles are able to pass those blood
vessel walls and they will subsequently be retained in the tissues that they have
entered. This so-called enhanced retention and permeation (EPR) effect provides
some level of selectivity in drug targeting.
Since passive targeting utilize blood circulation and extravasation in drug delivery
process, administrated drug usually also end up accumulated in other organs, in
particular liver, spleen, kidney, and lungs. This is where an "active targeting" can
help the enhancement of drug delivery through specific ligand-receptor interaction
between drug carrier and target cells [152, 153, 154]. However, even though refered
as "active targeting", ligand-receptor interactions are actually only possible when
both are in a very close proximity. Therefore, it is necessary to combine both passive
and active targeting, where drugs are being circulated by blood and extravasation
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Figure 3.1: Illustration of active and passive targeting in drug delivery system [155]
before it gets close enough to target area for the active ligand-receptor interaction to
happen. General illustration of active and passive targeting in drug delivery system
is shown in Fig 5.1.
3.1.2 Nanocarriers as Drug Delivery System
In the past few decades, nanotechnology has been through siginificant progress on its
application in medical field as the drug delivery system. Nanocarriers encompassing
materials with size range of 5-200 nm for the optimum effectivity of delivering drug
into target site as described in Fig 5.2 [156]. These nanocarriers are designed to
improve the circulation time and enhance drug accumulation through the passive
targeting.
Liposomes, which are vesicles having membranes made of double layers of phos-
pholipids, for example, has been developed as drug delivery system because it retains,
targets, and releases drug into the tumour site effectively during neutron irradiation
[79]. Because of their size, hydrophobic and hydrophilic character, biocompatibility,
biodegradability, low toxicity and immunogenicity, liposomes are promising systems
for drug delivery. And also, by varying the type of phospholipid used to make lipo-
somes and/or by attaching certain molecules to the surface of liposomes, they can be
engineered to have many useful properties.
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Figure 3.2: Systems and strategies used for drug targeting to tumors. A-E: Drug
targeting systems. Liposomes and liposomal bilayers are depicted in gray, polymers
and polymer-coatings in green, linkers allowing for drug release and for sheddable
stealth coatings in blue (rectangles), targeting ligands in yellow (arrows), antibodies
and antibody fragment in purple, imaging agents to monitor biodistribution and
target site accumulation in orange (suns), and conjugated or entrapped (chemo-)
therapeutic agents in red (stars) [156]
On the other side, micelles, are an aggregate of surfactant molecules dispersed in
a liquid colloid with only tens of nanometers in diameter and are thus ideally sized
for enclosing individual drug molecules. Polymeric micelles hats, made up of polymer
chains, are usually spontaneously formed by self-assembly in a liquid. The main ad-
vantages of this system are the possibility to incorporate a variety of drugs including
hydrophobic substances, metal complexes, and charged macromolecules such as nu-
cleic acids as well as control their release properties by engineering and modification
of the micelle-forming block copolymers [78].
Nanoparticles, especially, are getting attention as carrier device because of its ca-
pability in improving the pharmacological properties of conventional drugs due to
its advantages over low molecular weight agents for example large loading capacity,
capability to protect the payload from degradation, specific targeting, and controlled
or sustained release [157]. Modifying the characteristic such as the nanoparticles’size,
charge, and surface coating, might enhance the capability of nanoparticles in deliver-
ing drugs into target tumor [158].
Most of nano-sized agents accumulate into tumor site passively due to the EPR
effect [159]. The core of nanoparticles can contain small (or bigger) molecules such
as therapeutic drugs, while the shell provides interactions with the solvent and make
the nanoparticles thereby stable in the liquid. For example polymeric micelles, which
are either formed from block copolymers by ionic or by hydrophobic interactions, are
34
mentioned ot have several advantageous features over conventional surfactant micelles
that make them interesting as drug delivery system. Nanomicelles made up of a well-
defined core-shell architecture and the core of amphiphilic block copolymer micelles
is capable to accommodate poorly water-soluble drugs that are otherwise difficult to
administer to the body. The hydrophilic shell provides colloidal stability to the whole
assembly [160, 161, 162].
Another key requirement for an ideal drug delivery system is that its particle size
should be less than 150nm in order to efficiently target tumors [163, 164]. Small
size particles (about 100 nm) were reported to be ideal to avoid uptake by liver
macrophages and the reticuloendothelial system (RES) [165, 166] and to deliver
molecules to specific tissues of interest [167]. Having a prolonged circulation time
in blood is also critical because it has been shown that there was a strong correla-
tion between the residence time of a drug delivery system in blood and its uptake
by implanted tumors in mice [168]. A longer blood circulation time is associated
with repeated passages of a high concentration of the delivery system through the
tumor microvascular bed, and thus a greater efficiency of extravasations per unit vol-
ume of the transports. PEGylation is one method, which has been utilized widely
to modify pharmacokinetics of nanoparticles. Several reports have mentioned that
PEGylation have increased systemic circulation time of nanoparticles as drug carrier
[169, 170, 171].
Stability of nanoparticles is also an important factor in optimizing blood circula-
tion and drug accumulation in target cells. Because the critical micelle concentration
(CMC) of a block copolymer can be several orders of magnitude lower than that
of a ’classical’ surfactant, micelles are also highly resistant against dilution that is
unavoidable when administered to the patient (e.g. by injection), which increase its
physical stability [160]. However, the use of nanoparticles as drug delivery system
also have few drawbacks and limitations. Its small size and large surface area might
cause aggregation between nanoparticles. There is also a possibility of low loading
capacity and efficiency of desired drug. Technical modification is then necessary to
optimize medical application of nanoparticles as drug delivery system. A detail review
on targeted drug delivery is recently summarized by Bae and Park [172].
3.2 Nanoparticles as NCT Delivery Agent
The application of nanoparticles as drug delivery system in NCT has been investigated
extensively by many researchers worldwide. Promising results have been presented
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showing the effectivity of those systems in increasing the accumulation of NCT agent
in tumor site, which is expected to enhance the effect of cancer cells killing after
neutron capture reaction.
3.2.1 Drug Delivery System in BNCT
A more promising method is to introduce boron compound into nanosize dryg deliv-
ery system such as liposome and nanoparticles to enhance the uptake and retention
of boron during neutron irradiation. Our group was the first to apply liposomes as
boron carrier in BNCT and had shown that immunoliposome could serve as selective
and efficient carriers of 10B atoms to target tumor cells [173], continued with several
application of drug delivery system on BNCT [174, 175, 176]. Since then, a lot of
promising results of prolonged blood circulation as well as high retention of boron
in tumor site, had been reported on the use of liposome and nanoparticles as boron
carriers in NCT [177, 178, 179, 180]. Anti-epidermal growth factor receptor (EGFR)
monoclonal antibody (mAb) is one of the promising targeting agent as reported by
Yang and co-workers [181] with an extensive studies on EGFR targeting MoAb ce-
tuximab [182]. A review on several other boron-containing nanoparticles has been
reported elsewhere [183].
3.2.2 Drug Delivery System in GdNCT
Le UM [184] has previously developed improved method in the uptake and reten-
tion of gadolinium with a pegylated liposome encapsulating Gd-DTPA MRI contrast
agent. It is mentioned that the liposome increase blood circulation of drug carrier
and capable of accumulating gadolinium higher than 50 µg per gram tumor wet tis-
sue. Previously, we have also performed in vivo experiment on tumor-bearing mice
with gadolinium encapsulating liposome gadoteridol MRI contrast agent, where we
could observe enhancement of gadolinium accumulation in tumor site of liposome-
encapsulated gadoteridol compared to the group injected with a free gadoteridol [84].
Research group in Kobe Gakuin University, who have been working on nanopar-
ticles as gadolinium carrier in NCT, have reported their work on chitosan nanopar-
ticles containing gadolinium developed and synthetized for radiosensitization [185,
186]. This nanoparticles has successfully been incorporated into cells in vitro, with
higher incorporation than molecular contrast agents. After intratumoural injection in
melanoma-bearing mice, thermal neutron irradiation was applied to the tumor site,
and tumor growth delay was observed indicating GdNCT effectivity [187].
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Chapter 4
KURRI Nuclear Reactor Facility for
NCT Treatment
4.1 General Description of The Facility
Nuclear reactor facility at Kyoto University Research Reactor Institute in Kumatori,
Osaka, has been operated not only in clinical trials for treating several types of cancer,
but also for the application on many research fields such as physics, engineering,
agriculture, biology, etc. The Heavy Water Neutron Irradiation Facility (HWNIF)
was updated in March 1996; mainly for an improvement in boron neutron capture
therapy (BNCT). This facility has a heavy water tank of approximately 2 m3 adjacent
to the KUR core with the layout of KUR Advanced Clinical Irradiation System shown
in Fig Fig. 4.1 including the HWNIF, and the outline of the HWNIF facility is given
in Fig. 4.2.
Due to the update in March 1996, the utility and application of the facility for
NCT clinical irradiation is thought to be remarkably improved. Especially in the
performance, neutron irradiation with several neutron energy spectra, from almost
pure thermal neutrons to epithermal neutrons, became available by the control of the
heavy water thickness in the neutron energy spectrum shifter and the aperture sizes
of the thermal neutron filters of cadmium and boral. The HWNIF has an irradiation
field of 54 cm diameter on the bismuth layer surface, and it is available for the wide-
area and uniform neutron irradiation. Also, by the installation of irradiation rail
deive and remote caryying system, the irradiation utilization is more extensive for
size and shape of irradiated sample [188].
A clinical irradiation for neutron capture therapy at the facility was carried out in
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Figure 4.1: Layout of the KUR Advanced Clinical Irradiation System [188].
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Figure 4.2: Outline of the Heavy Water Neutron Irradiation Facility of the Kyoto
University Research Reactor [189].
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Figure 4.3: Nuclear reactor facility of Kyoto University Research Reactor Institute.
Clockwise from top left: irradiation bed for patient treatment, irradiation setup for
animal experiment on the neutron beam window, view of entrance door to the irra-
diation room, control panel and monitoring system during irradiation.
May 1974 for the first time, and it has been regularly performed since February 1990.
By November 1995, just before the remodeling, 61 clinical trials were carried out for
6 yr [190]. As of the end of March 2011, 315 NCT clinical irradiations have been
performed, namely, 168 for brain tumours, 105 for head and neck tumours, 22 for
malignant melanomas, 7 for lung tumours, 7 for liver tumours, and 6 for tumours of
the other body-parts, using the three standard irradiation modes of thermal-neutron,
mixed-neutron and epi-thermal neutron. Treatment room and the control panel for
patient treatment as well as the animal experiment facility can be seen in Fig. 4.3.
4.2 Neutron Spectra and Beam Characteristics of
HWNIF
The calculated energy spectrum for each neutron and photon used for NCT animal
experiment is given in Fig. 4.4. Here the operation mode is OO-0000-F with operating
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power of 1 MW. Sakurai and Kobayashi [188] have also reported the measured data
for gamma-ray dose equivalent rate on the vertical axis and the thermal neutron flux
on the horizontal axis for OO-yyyy-F mode group (Fig. 4.5). Unexpectedly, the
measured gamma-ray doses are not perfectly proportional to the thermal neutron
flux. These relations between the gamma ray dose rate and the thermal neutron flux
are thought to be dependent on the mixing ratio of the other components.
In the heavy water tank, an aluminium-heavy water mixture (Al/D2O=80/20
in volume percent), and a neutron-energy spectrum shifter of heavy water whose
thickness changed from 0 to 90 cm, are installed in order from the core side. Outside
of the spectrum shifter, two thermal neutron filters of 1mm-thick cadmium plate
are installed. The energy spectrum of the neutron beam can be controlled from
almost pure thermal to epi-thermal within five minutes by remote control under a
continuous reactor operation [189]. The overview of neutron flux and absorbed dose
rate on different operation mode of KUR is given in Fig. 4.6.
The thermal neutron irradiation of HWNIF is suitable for a tumor seated near
the surface such as melanoma, etc., but its application is limited for deep-seated
brain tumor, etc. On the other hand, for solo irradiation of epi-thermal neutrons,
its irradiation characteristic is a merit for treatment of deep-seated tumor, however,
the shallow part may not be sufficiently irradiated by thermal neutrons. Application
of mixed neutron irradiation has also been proposed to compensate the respective
demerits of thermal and epi-thermal neutron depending on the depth of the treated
tumor [188].
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Figure 4.4: Calculated spectra of neutron and gamma source on the exit window of
neutron irradiation at HWNIF of the KURRI.
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Figure 4.5: Relation between the thermal neutron flux and the gamma-ray dose
equivalent rate at the normal irradiation position for the OO-yyyy-F mode group
[188].
The beam parameters in free-in-air condition for the xx-0000-F mode group
 Irradiation mode Neutron ﬂux (cm 2s     )1    Absorbed dose rate (cGy/h)
  Thermal Epithermal Fast
OO-0000-F 4.98E+09 7.99E+08 4.74E+07 2.42E+02    
CO-0000-F 3.04E+07 7.28E+08 4.74E+07 2.38E-01 2.24E+01 1.63E+02 6.20E+01
OB-0000-F 1.59E+07 3.88E+08 4.59E+07 5.39E-01 1.89E+01 1.60E+02 5.00E+01
CB-0000-F 4.55E+06 3.82E+08 4.60E+07 3.51E-02 1.89E+01 1.60E+02 5.00E+01
   Thermal Epithermal Fast Gamma-ray
1.63E+02 3.30E+022.29E+01
Figure 4.6: Neutron flux and absorbed dose rate for four types of KUR’s operation
mode [189].
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Chapter 5
Evaluation of Gadolinium-Platinum
Nanomicelles as NCT agent
5.1 Introduction
One of the key factors for the success in GdNCT is to deliver and maintain sufficient
amount of gadolinium in tumor tissues during the neutron irradiation. Thus, effective
drug delivery systems are needed in order to deliver sufficient amount of Gd into tu-
mors for the optimization of GdNCT. Gadolinium-platinum nanomicelles compound
used in this research is a continued work from previous investigation, in which we
expected to combine radiotherapy effect from GdNCT with chemotherapy effect from
commonly used oxaliplatin.
Combination therapy has been nowadays getting more attention because it showed
improved outcome from the different mechanisms of drugs that help to attack multiple
targets. Sometimes, low-dose chemotherapy and/or radiation therapy after surgery
can help to destroy any remaining cancer cells. Another time, they were given before
the surgery to shrink the tumors, thus providing greater ease in tumor removal. Fre-
quently, radiation and chemotherapy or many chemotherapy agents were also incor-
porated together for the treatment of advanced and metastatic cancers [184]. There-
fore, by combining citotoxicity effect from platinum as chemotherapy agent and the
ionization from secondary particles of GdNCR, better tumor suppression from the
improvement of cancer cells killing effect might be achieved. It is expected that we
could shorten the irradiation time, reduce total injected drug dose, and eventually
improve patient’s quality of life.
The Gd-DTPA/DACHPt-loaded nanomicelles was kindly provided by Kaida and
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co-workers [78] where Gd-DTPA, a widely used MRI contrast agent, is incorporated
together with DACHPt in micelles core. The polymeric micelles was developed as
a self-assembly of amphiphilic block copolymers consisting of hydrophobic segments
forming the drug-loaded core and water-soluble segments forming the biocompatible
shell. The main advantages of this system are the possibility of incorporating a variety
of drugs as well as controlling their release properties by engineering and modifying
the micelle-forming block copolymers. Moreover, polymeric micelles can be designed
to be responsive to environmental changes and capable of target recognition [78]. It
is also mentioned that some clinical studies have revealed that polymeric micelles
showed reduced side effects and high effectiveness to various intractable tumors.
Radiosensitizing possibility of platinum-based drugs in combined modality treat-
ment has actually been studied intensively in medical field. Cisplatin for example,
is widely accepted as potentially radiosensitizing and combined modality treatment,
including radiotherapy and cisplatin, is now frequently and successfully used in the
treatment of lung cancer and cervical cancer [191]. Nevertheless, increased acute and
late toxicity effects have been reported in several cases that stirred the resistance of
this combined modality. Therefore, it is necessary to perform thorough research for
combined radiochemotherapy with superior efficacy and less toxicity.
5.2 Materials and Methods
5.2.1 Nanomicelles Preparation
The micelles was developed as a theranostic core-shell polymeric micelles based on
the self-assembly of block copolymers with both a magnetic resonance imaging (MRI)
function and cancer therapeutic capacity. It incorporates gadolinium-diethyl
enetriaminepentaacetic acid (Gd-DTPA), a widely used T1-weighted MRI contrast
agent, and (1,2-diaminocyclohexane)platinum(II) (DACHPt), the parent complex of
the potent anticancer drug oxaliplatin, in their core by reversible complexation be-
tween DACHPt, Gd-DTPA, and poly(ethylene glycol)-b-poly(glutamic acid) [PEG-
b-P(Glu)] as illustrated in Fig. 5.1. Briefly, Gd-DTPA was converted to sodium salt
by adjusting the pH to 7 with NaOH, and it was lyophilized. A 5 mmol/L solution
of bis(nitrato) (trans-l-1,2-diaminocyclohexane) platinum(II) [DACHPt(NO3)2; W.C.
Heraeus GmbH & Co. KG] in water was mixed with the sodium salt of Gd-DTPA
(5 mmol/L), and the solution was maintained for 24 hours at 37 Â◦C. Then, PEG-b-
P(Glu) ([Glu] = 5 mmol/L) was added to this solution ([DACHPt]/[Glu] = 1.0) and
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reacted for 120 hours at 37 Â◦C to prepare Gd-DTPA/DACHPt-loaded micelles. The
resulting micelles were 33 nm in diameter, which is considered to be small enough
to pass through the leaky vasculature of solid tumors and attain deep tumor pen-
etration. Accordingly, both the DACHPt and Gd-DTPA complexes, which can be
excreted from the kidney, thus avoiding toxicity from long-term accumulation inside
the body, are released from the micelles in a sustained manner under physiologic
conditions [78].
It had been shown that the incorporation of Gd-DTPA into the micelles did not
influence the anticancer effect of the oxaliplatin in the micelles. Additionally, it is
reported that the micelles have continuous and strong anticancer effect and enhance
the MRI contrast of the tumor region in an orthotopic human pancreatic cancer
xenograft model much more intensely than Gd-DTPA alone, although the diagnosis
and treatment of pancreatic cancer has been considered to be the most difficult among
digestive cancers. Thus, the Gd-DTPA/DACHPt-loaded micelles are expected not
only to improve the effectiveness and safety of the incorporated drugs but also to
assist in the real-time monitoring of the drug distribution and tumor accumulation,
suggesting the great potential of visible DDS [78].
5.2.2 Cancer cells Line and Mice Preparation
In current study, we used colon-26 tumor cells injected subcutaneously into tumor
bearing mice. Mouse colon carcinoma cell line Col 26 was obtained from Dainihon
Seiyaku Co. Ltd. (Osaka, Japan). Colon-26 was maintained in RPMI 1640 medium
(Hazleton Biologics, INC, Kansas, USA) supplemented with 10% fetal calf serum
(Cell Culture Laboratories, Ohio, USA) and 100 mg/ml 1 kanamycin. All cultures
were incubated in high moisture air with 5% CO2 at 37 C. The medium was changed
routinely three times a week.
Male BALB/c mice were obtained from Nihon SLC (Shizuoka, Japan) and used
at 6-7 weeks of age. In each experiment, mice of similar age and weight were selected.
Mice were housed in plastic cages and maintained in an air-conditioned room. Tumor
models were prepared by subcutaneous injection of 1 × 105 of Col-26 cells into right
femoral of the mice. The tumor was let to grow for two weeks until the average
volume reached 100 mm3. The procedures for tumor implantation and sacrifice of
the animals were performed with permission of the Animal Ethics Committee of The
University of Tokyo in accordance with the Declaration of Helsinki.
46
Figure 5.1: The schematic diagram of self-assembly Gd-DTPA/DACHPt-loaded na-
nomicelles and the release of platinum and gadolinium complexes from the micelles
in chloride-containing medium [78].
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5.2.3 Biodistribution Analysis
In this experiment, MRI image acquisition was performed to take cross section image
of each mouse using the MRI facility in Kashiwa campus The University of Tokyo. An
MRI machine uses a powerful magnetic field to align the magnetization of some atomic
nuclei in the body, and radio frequency fields to systematically alter the alignment
of this magnetization. This causes the nuclei to produce a rotating magnetic field
detectable by the scanner and this information is recorded to construct an image of the
scanned area of the body [192]. Gradients in magnetic field cause nuclei at different
locations to rotate at different speeds. By using gradients in different directions 2D
images or 3D volumes can be obtained in any arbitrary orientation.
MRI provides good contrast between the different soft tissues of the body, which
makes it especially useful in imaging the brain, muscles, the heart, and cancers com-
pared with other medical imaging techniques such as computed tomography (CT) or
X-rays. Unlike CT scans or traditional X-rays, MRI does not use ionizing radiation
which is one of the most important aspects to be considered when we apply treatment
or diagnosis to the patient.
When a person is inside the powerful magnetic field of the scanner, the average
magnetic moment of those protons inside human body becomes aligned with the same
direction as of the magnetic field. When a radio frequency transmitter with just the
right frequency is applied, it is then being absorbed and flips the spin of the protons
in the magnetic field. After the electromagnetic field is turned off, the spins of the
protons return to thermodynamic equilibrium and the bulk magnetization becomes
re-aligned with the static magnetic field. During this relaxation, a radio frequency
signal is generated, which can be measured and give information of the scanned object.
Different tissue variables, including spin density, T1 and T2 relaxation times and flow
and spectral shifts can be used to construct images. By changing the settings on the
scanner, this effect is used to create contrast between different types of body tissue
or between other properties, as in fMRI and diffusion MRI [193].
To enhance contrast appearance of blood vessels, tumor, or inflammation, a con-
trast agent is usually utilized by injecting certain elements, which has the capabil-
ity of shortening the T1 relaxation time of protons during imagin acquisition pro-
cess. And the most commonly used compounds for contrast enhancement in MRI are
gadolinium-based compound including the two gadolinium-based compound that we
use in current study. Gadolinium has the ability of altering the relaxation times of
tissues and body cavities where they are being accumulated. Therefore, it enhances
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Figure 5.2: Experimental set-up for MRI image acquisition.
brightness contrast of tumor site, which normally appears darker and might not show
good matter contrast.
For the MRI image acquisition, mice were injected with Gd-DTPA/DACHPt-
loaded micelles intravenously and fixed in the custom-made cradle with nylon tape.
The mice were anesthetized with 5% isoflurane at the beginning and maintained with
1.5% isoflurane during the MRI image acquisition. MRI images were obtained using
a 4.7 Tesla superconductive magnet unit interfaced to a Varian (UNITY INOVA,
Varian Inc., Palo Alto, CA) with 60mm diameter birdcage RF coil and maximum
imaging gradient of 6.0 Gauss/cm. For the T1 -weighted MR imaging of live mice,
the following parameter were adopted: spin-echo method, the repetition time (TR)
= 300 ms, the echo time (TE) = 15 ms, the field of view (FOV) = 40 × 40 mm2 for
axial direction and equals 50 × 50 mm2 for coronal and sagittal direction, matrix size
= 128 × 128 and the slice thickness = 2 mm. Fig 5.2 shows the experimental setup
for MRI image acquisition.
For the quantitative analysis, ICP-MS measurement was performed to evaluate
total gadolinium and platinum concentration in tumor-bearing mice organs. For
the in vivo experiments, injected-mice were sacrificed at 2, 12, and 24 hours after
gadolinium compound injection then tumor and several vital organs such as blood,
liver, kidney, spleen, heart and lungs were excised. Volume of each organ sample was
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Tumor site at 
mice leg
LiF shielding
Figure 5.3: Neutron irradiation setup at KUR facility. Mice were held within acrylic
tube and neutron beam was collimated to tumor site on the leg using LiF shielding.
measured, followed by digestion in HNO3 left overnight. Samples were then digested
in microwave oven to ensure that all of the sample material is dissolved. The total
amount of gadolinium was measured using ICP-MS and the results were normalized
to the tissue volume.
5.2.4 Neutron Irradiation
Neutron irradiation for Gd-DTPA/DACHPt-loaded nanomicelles-injected group was
performed at Heavy Water Neutron Irradiation Facility (HWNIF), Kyoto University
Research Reactor Institute in Kumatori, Osaka. Operation mode for this irradiation
is OO-0000-F with operating power of 1 MW. Rectangular tiles made of 6LiF were
chosen as the collimator material to shield all mice body but the tumor area from
thermal neutrons. Irradiated mice were held within acrylic tube designed specifically
for collimated neutron irradiation as illustrated in Fig. 5.3, where neutron beam
direction is into the page. Neutron fluence for this experiment was measured by
gold foil on the surface of the tube where mice were placed for the irradiation, while
gamma-ray dose component was monitored by using TLD placed at the same point
as gold foils.
In previous work, we performed whole body irradiation at JRR-4 nuclear reac-
tor facility and observed high toxicity for Gd-DTPA/DACHPt-loaded nanomicelles-
injected irradiated at two hours after drug administration. Therefore, the experi-
ment was then previously continued with neutron irradiation at 24 hours after Gd-Pt
compound injection where gadolinium concentration in blood plasma has already de-
creased significantly, to minimize ionizing effect to normal tissues. For this second
50
Tumor site at 
mice leg
LiF shielding
(a)
Tumor site at 
mice leg
LiF shielding
(b)
Figure 5.4: a. Irradiation set-up for collimated neutron using LiF sheet with 2×1012,
1 × 1012, and 0.5 × 1012 n/cm2 neutron fluence. b. Experimental set-up for whole-
body-neutron-shielded irradiation. Neutron irradiation was exposed perpendicular to
LiF sheet.
experimental procedure, we performed neutron irradiation with the setup as shown
in Fig. 5.4(a) and Fig. 5.4(b) within these conditions:
• Collimated irradiation onto tumor site of the mice using LiF shielding with three
different neutron fluence to evaluate the effect from various neutron irradiation
doses. The thermal neutron fluence for the experiment were approximately
2 × 1012 n/cm2 (35 minutes irradiation time), 1 × 1012 n/cm2 (17.5 minutes
irradiation time), and 0.5× 1012n/cm2 (9 minutes irradiation time).
• Whole body neutron-shielded irradiation using LiF sheet to check the possibility
of radiation effect from gamma contamination in the neutron beam,
Following this experiment, we also then performed neutron irradiation on mice
group injected with Gd-DTPA/DACHPt-loaded nanomicelles and oxaliplatin-loaded
nanomicelles only (without Gd-DTPA), to confirm the possibility of platinum pho-
toactivation toxicity of Gd-DTPA/DACHPt-loaded nanomicelles after neutron irra-
diation. Neutron irradiation was carried out for injected mice group both at 12 hours
and 24 hours after injection. Considering that platinum accumulation in blood at
12 hours is still quite high, and it decreases significantly at 24 hours after injection,
it is expected that we could investigate whether the cause of high toxicity observed
for this nanoparticles in previous experiments is associated with the irradiation of
platinum only.
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5.2.5 Evaluation of Antitumor Effectivity
To evaluate antitumour effectivity after neutron irradiation, tumor growth suppres-
sion needs to be monitored periodically altogether with the weight. Tumour size of
each mouse was measured every two or three days until about one month from the
first day of neutron irradiation. Tumor volume calculation was carried out using the
formula:
V = a× b
2
2
(5.1)
where a and b are the major and minor axes of the tumour measured by a caliper,
respectively. Mice body weight was also monitored simultaneously as a parameter
of systemic toxicity. The antitumor effect was evaluated on the basis of the change
in tumor growth and survival rate of the mice. We also evaluated survival rate
for experiment and plotted the Kaplan-Meier to estimate survival fraction of treated
mice on the experiment with various neutron fluence until about 36 days after neutron
irradiation.
5.3 Results and Discussions
5.3.1 Biodistribution Analysis
Coronal MRI image of tumor-bearing mice was taken after administation of 0.2 ml Gd-
DTPA/DACHPt-loaded nanomicelles to observe macroscopic distribution of gadolin-
ium. Unfortunately, on the MRI image acquisition time, we could not provide free
Gd-DTPA for comparison of image enhancement, so we used MRI image data of
gadoteridol-solution from previous investigated gadolinium-encapuslating liposome
[84].
Contrast signal in gadolinium-platinum compound shown in Fig. 5.5 was not
that much different compared to the MRI image of the gadoteridol-solution, even
though the initial amount of gadolinium contained in 0.2 ml of gadoteridol-solution
was actually almost 1000 times higher compared to those contained in 0.2 ml of
Gd-DTPA/DACHPt-loaded nanomicelles. Therefore, toretically we can say that
Gd-DTPA/DACHPt-loaded nanomicelles could accumulate much larger amount of
gadolinium into the tumor site compared to free gadoteridol-solution. Better con-
trast enhancement of Gd-Pt nanomicelles compared to free Gd-DTPA is given in Fig.
5.6 from Kaida and co-workers’ work [78], where the injected Gd-DTPA dose is in-
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Figure 5.5: Transversal cross section MRI image comparison between Gd-Pt nanomi-
celles and gadoteridol-solution. Tumor site is shown by white dash circle and the
number under each MRI image indicates the approximation of total signals for tumor
site area.
creased up to 2.5 times higher compared to the injected dose we used to acquire MRI
image in Fig. 5.5.
The result of ICP-MS measurement is presented in Fig. 5.7, which shows signif-
icant decreasing tendency of gadolinium and platinum concentration in blood, and
increasing accumulation of platinum in tumor site, which agrees with the character-
istics reported by Kaida and co-workers [78]. Gadolinium accumulation in tumor site
is increasing at 24 hours after injection, which is also in agreement with the result
presented in their paper [78].
5.3.2 Neutron Irradiation
Average neutron fluence measured by gold foil for the 60 minutes irradiation is 2.7 ×
1012 n/cm2 for thermal neutron range and 4.75 × 1011 n/cm2 for epithermal neutron
range. Physical dose from the measurement during neutron irradiation are shown in
Table 5. 1. It is defined that thermal neutron region is below 0.5 keV, the epithermal
neutron region is 0.5 keV-10 keV and the fast neutron region is over 10 keV. These
results are also comparable to physical dose meausured in the GdNCT experiment
performed by other researchers at the same reactor facility in KUR [187].
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Figure 5.6: In vivo MRI images of T1-weighted transaxial slices of C-26 subcutaneous
tumor after i.v. injection of Gd-DTPA/DACHPt-loaded micelles compared to bare
Gd-DTPA at 5 µmol/kg Gd-DTPA [78]).
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Figure 5.7: ICP-MS measurement results of gadolinium and platinum concentration
accumulated in tumor site and plasma blood. Error bar indicates the uncertainty of
ICP-MS and variance of samples.
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Table 5.1: Average physical dose from the measurement during neutron irradiation
Physical dose (Gy)
Thermal neutron (∼0.5eV) 3.6 × 10−1
Epithermal neutron (0.5eV∼10keV) 3.85 × 10−2
Fast neutron (10keV∼) 2.65 × 10−1
Gamma ray 4.35 × 10−1
Total 1.1
Natural gadolinium (1ppm) 3.55 × 10−3
Gadolinium-157 (1ppm) 1.85 × 10−2
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Figure 5.8: Tumor growth suppression after neutron irradiation of various fluence
for Gd-Pt nanomparticles injected group. Data shown is average tumor growth ratio
from 4-5 mice on each group with error bar indicating variance of measured data.
5.3.3 Evaluation of Antitumor Effectivity
Evaluation of antitumor effect was performed in the same procedure with the previ-
ous experiment on gadolinium-entrapped lipoosme for GdNCT [84]. For each treat-
ment condition, we included at least 3 control mice (for non-injected and gadolinium-
solution injected group) as a standard for comparison of the antitumor effect evalua-
tion. Tumor sizes were measured until 24 days after neutron irradiation and the result
for the experiment with various neutron fluence is shown in Fig. 5.8. Non-treated
group is not shown in this graph, but the tumor growth suppression was observed to
be around 5 times higher compared to the control (non-treated) non-irradiated group.
Unfortunately, even for this experimental set-up, almost all irradiated mice, which
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were injected with Gd-DTPA/DACHPt nanomicelles died within 10 days after irra-
diation. Only two mice from group irradiated with 1 × 1012 n/cm2 neutron fluence
survived until 24 days of evaluation (as described in the Kaplan Meier plot in Fig.
5.9). We can see that mice received no treatment mostly survived until more than
20 days after neutron irradiation. Some non-treated mice even survived until 33 days
after irradiation. Gd-DTPA/DACHPt nanomicelles-injected group in this experiment
still showed quite high toxicity and low survival rate. Significant prolongation of sur-
vival rate for Gd-DTPA/DACHPt nanomicelles-injected mice was observed on group
irradiated with 1× 1012 n/cm2 neutron fluence, even though only 60% survived until
27 days after neutron irradiation, the same as non-treated mice for 1 × 1012 n/cm2
neutron fluence.
Even though we have performed collimated irradiation so that neutron will be
restricted into tumor site only for this second experiment, the toxicity still seemed
to be quite severe and caused death to most of the tumor-bearing mice within 9
days after thermal neutron irradiation. Irradiation with neutron-shielded experiment
also showed 100% mice death within 9 days after irradiation. This shows higher
possibility that gamma dose from neutron beam of the reactor facility have caused
photoactivation of platinum and might as well gadolinium which also accumulated at
several organs of the mice and deposit quite significant ionizing radiation dose.
Since current irradiation was performed with the standard clinical trial neutron
fluence, our previous assumption is that platinum photoactivation occurs during irra-
diation that increases the compound toxicity. Thermal neutron cross section for nat-
ural platinum is very small (0.96 barns), therefore it is unlikely that platinum neutron
capture reaction caused the high toxicity of this compound after neutron irradiation.
However, since platinum K-edge shell is 78.39 keV, while gamma contamination in
neutron beam have energy range above that K-edge shell energy, platinum photoac-
tivation is very likely to occur and increase the toxicity of platinum element in mouse
body.
Gd-DTPA/DACHPt-loaded nanomicelles-injected mouse were actually showing
enhancement of tumor growth suppression compared to control group. Slight differ-
ence of tumor growth suppression effect was also observed compared to bare platinum
irradiated group, indicating GdNCT effect even with low gadolinium concentration
(below 1 ppm) in tumor site.
For the following experiment of neutron irradiation for mice group injected with
both Gd-DTPA/DACHPt-loaded nanomicelles and oxaliplatin-loaded nanomicelles
only, tumor growth suppresion graph after GdNCT treatment is given in Fig. 5.10.
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Figure 5.9: Kaplan Meier plot for experiment of neutron irradiation with different
fluence on mice injected with Gd-DTPA/DACHPt-loaded nanomicelles
We still observed severe toxicity on the irradiated group for both nanomicelles-injected
mice, where both nanomicelles-injected and irradiated mice group died within 10 days
after neutron irradiation. Mice weight by time is also presented in Fig. 5.11, where
we could observe that the weight loss for almost all group have the similar tendency
until around 9 days after irradiation. However, all irradiated mice did not recover
(while the non-irradiated group did) and died within 10 days after irradiation.
Previous study by [194] presented on (Tabel 5.2.) summarizes six in vitro studies
analyzing the radiosensitizing potential of oxaliplatin. The results showed that an
enhanced cytotoxic effect was obtained when the two treatments (oxaliplatin and high
LET radiation) were combined taking either cell proliferation or clonogenic survival
as an endpoint. This means that the effects of a combined radiation and oxaliplatin
treatment are greater than the sum of the respective single responses, irrespective of
being termed additive, supra additive or synergistic.
Up to date, the mechanisms causing radiosensitizing properties of oxaliplatin have
not been studied in detail. Like cisplatin, oxaliplatin acts as an alkylating agent on
DNA, but differences in their DNA-adducts and mechanisms of DNA-repair may be
related to their specific activity profiles. Oxaliplatin forms DACH-platinum adducts
which are more bulky and hydrophobic and possibly more effective in inhibiting
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Figure 5.10: Tumor growth suppression for Gd-DTPA/DACHPt-loaded nanomicelles
compared to DACHPt-nanomicelles injected group irradiated at 12 hours and 24
hours after compound injection, compared to the non-irradiated group. Data shown
is average tumor growth ratio from 4-5 mice on each group with error bar indicating
variance of measurement.
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Figure 5.11: Mice weight loss after neutron irradiation for mice group injected with
Gd-DTPA/DACHPt-loaded micelles and DACHPt-loaded micelles only. Data shown
is average mice weight from 4-5 mice on each group with error bar indicating variance
of measured data.
DNA-synthesis and repair [203]. Eventhough we could observe slight difference of
tumor growth suppression compared to the non-irradiated group with significantly
low gadolinium concentration, the high toxicity results suggested that the feasibility
of combined radiochemotherapy for Gd-Pt nanomicelles is difficult to achieve within
tolerable toxicity with current experimental setup of injected dose and neutron irra-
diation dose.
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Chapter 6
Evaluation of Gd-DTPA/CaP
nanoparticles as NCT Agent
6.1 Introduction
As continued interest on the application of nanoparticles-based drug carrier for NCT
agent, in this work we carried out the feasibility evaluation of calcium phosphate
(CaP) nanoparticles as Gd-DTPA delivery device for GdNCT agent.
Calcium phosphate nanoparticles have gained increasing interest in medical appli-
cation because of their high biocompatibility and good biodegrability due to the fact
that calcium phosphate is the inorganic mineral of human bone and teeth [204, 205],
and it is also not prone to microbiological degradation like organic or polymeric car-
rier systems [206]. Calcium phosphate are moderately soluble at pH 7.4 and become
increasingly soluble below pH 6 [207], which makes it attractive for drug delivery
because CaP nanoparticles will remain intact during delivery to cells where rapid
pH decrease occurs after entering endolysosome [208]. Their size can also be easily
controlled by stabilizing agents such as polymers or nucleic acids [206].
Calcium phosphate-based nanoparticles can be synthesized by various methods
including wet chemical routes, solid-state reactions and hydrothermal reactions at
elevated temperature, biosyntetic routes, and microemulsion. The efficiency of these
syntheses depends on several parameters, including calcium and phosphate ion con-
centrations, pH, ionic strength, temperature, and surfactant concentration and type
[209]. With these advantageous characteristics of CaP nanoparticles, it is expected
that we could optimize gadolinium accumulation into tumor site to achieve higher
cancer cells killing effect after GdNCT treatment.
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Figure 6.1: Design and synthetic procedures scheme of Gd-DTPA/CaP nanoparticles
(adapted from [210]).
6.2 Materials and Methods
6.2.1 Nanomicelles Preparation and Characterization
An organic-inorganic nanoparticles of CaP core loaded with Gd-DTPA has been pre-
viously developed to enhance MRI contrast in solid tumors, where Gd-DTPA/CaP
nanoparticles was prepared by mixing Gd-DTPA, PEG-b-PAsp, Ca2+ and HPO42−
in buffer followed by hydrothermal synthesis at 120 Â◦C for 20 min in Autoclave ma-
chine to increase Gd-DTPA/CaP nanoparticles stability in wet environments [210].
This technique has been proven to increase the colloidal stability of CaP nanoparticles
in physiological condition and enhance the relaxivity of Gd-DTPA after loading in
CaP nanoparticles. Preparation scheme of Gd-DTPA/CaP nanoparticles preparation
is shown in Fig. 6.1.
For the characterization of Gd-DTPA/CaP nanoparticles, we performed mea-
surement of average diameter by dynamic light scattering (DLS) using a Zetasizer
Nano ZS90 (Malvern Instruments, UK), while the morphology of Gd-DTPA/CaP was
confirmed using transmission electron microscope (TEM, JEM-1400, JEOL, Tokyo,
Japan). To visualize the accumulation of nanoparticles in cells, we performed calcein
staining during Gd-DTPA/CaP nanoparticles preparation by adding 0.1 mM calcein,
and carried out purification while avoiding light. Cancer cells were seeded in 4 cm
diameter dishes at a concentration of 1 × 105 cell/ml with 2 ml DMEM medium in
each well. After 24 hours, the calcein labeled Gd-DTPA/CaP with the concentration
of 100 µM gadolinium were added to the dishes and let to incubate for another 24
hours. The nuclei were then stained with Hoechst and evaluated with a LSM780
confocal scanning microscope (Carl Zeiss, Oberkochen, Germany).
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6.2.2 Cancer cells Line and Mice Preparation
Colon carcinoma Col-26 cells used in this experiment were kindly supplied by National
Cancer Center (Tokyo, Japan). The cells were maintained with DMEM supplemented
with 10% fetal bovine serum and then incubated in high moisture air with 5% CO2
at 37 C. Female BALB/c mice were obtained from Nihon SLC (Shizuoka, Japan) and
used at 6-7 weeks of age. Tumor models were prepared by subcutaneous injection of
1 × 105 of Col-26 cells into right femoral of the mice. The tumor was let to grow
for two weeks until the average volume reached 100 mm3. The procedures for tumor
implantation and sacrifice of the animals were carried out following the policies of the
Animal Ethics Committee of the University of Tokyo.
6.2.3 Biodistribution Analysis
We performed two biodistribution experiments of in vivo quantitative analysis, each
for single and multiple injections of Gd-DTPA/CaP nanoparticles. Intravenous in-
jections via tail vein were performed with the dose of 1.5 mM based on Gd-DTPA.
To confirm the pharmacokinetics of Gd-DTPA/CaP nanoparticles for 0.2 ml single
injection, we harvested tumor, blood, and other organ samples at 12 and 24 hours
following nanoparticles administration.
Three times injections of Gd-DTPA/CaP nanoparticles with 10 hours interval
were then carried out in order to achieve higher gadolinium accumulation in tumor
site. Tumor and blood samples were harvested at every 10 hours interval from the first
injection. Samples from both experiments were analyzed using inductively coupled
plasma mass spectroscopy (ICP-MS), where volume of each organ sample was mea-
sured, followed by digestion in HNO3 left overnight, and then digested in microwave
oven to ensure that all of the sample material is dissolved. The total amount of 157Gd
was measured using ICP-MS and the results were normalized to the tissue volume.
In addition to this, previously evaluated biodistribution analysis by MRI and micro-
synchrotron radiation-induced X-ray fluorescence spectrometry (µ-SR-XRF) will also
be presented.
6.2.4 Neutron Irradiation
We carried out 60 minutes neutron irradiation at The Heavy Water Neutron Irradi-
ation Facility of the Kyoto University Research Reactor (KUR-HWNIF) with OO-
0000-F beam mode and 1 MW operating power. Irradiated mice were held within
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Thermal NeutronTumor
LiFtiles
Figure 6.2: Illustration of tumor-bearing mice held in an acrylic tube prepared for
neutron irradiation with subcutaneous tumor on mice leg [211].
LiF collimator
Figure 6.3: Left: Front view of irradiation setup. Right: Backside view showing LiF
shielding plate.
acrylic tube designed specifically for collimated neutron irradiation as illustrated in
Fig. 6.2. Plate shielding of LiF with 5 mm thickness were placed between mice holder
and neutron beam to reduce neutron irradiation into parts of mice body other than
the tumor-bearing mice leg as shown in Fig. 6.3.
Neutron fluence was measured by gold foil at 2 points on the mice leg, while
gamma ray dose was measured by thermoluminescent dosimeter on the same points
with gold foil. For single-injected mice group, neutron irradiation was performed
24 hours following Gd-DTPA/CaP nanoparticles injection. While for the multiple-
injected tumor-bearing mice, experimental procedure is described in Fig. 6.4.
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Figure 6.4: Experimental procedure for multiple injections of Gd-DTPA/CaP
nanoparticles.
6.2.5 Evaluation of Antitumor Effectivity
Wit the same procedure as previous experiment, we measured mice tumor size every
three days after irradiation to evaluate the antitumor activity. Tumor volume was
calculated using the formula of
V = a× b
2
2
(6.1)
, where a and b are the major and minor axes of the tumor measured by a caliper,
respectively. Pathological analysis were also performed for tumor samples fixed on
OCT compound and frozen at -80◦C, resected on day 27th after neutron irradiation.
Harvested tumor samples were sliced into 6 µm sections with a cryostat and deposited
on glass slide before then stained with hematoxylin and eosin (H&E). TUNEL stain-
ing was also performed on the samples with the same slice thickness of 6 ÎŒm for
evaluation of possible apoptosis occured on cancer cells by detecting the DNA frag-
mentation following GdNCT treatment. Negative control for both irradiated and
non-irradiated groups was also prepared during the apoptotic assay.
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6.3 Results and Discussions
6.3.1 Characterization of Gd-DTPA/CaP Nanoparticles
Monodispersity and spherical shape of Gd-DTPA/CaP nanoparticles were confirmed
by TEM images as shown in Fig. 6.5A, with calculated volume-averaged diameter of
60 nm (Fig. 6.5B). These small size nanoparticles (<100nm) are hardly recognized
by the immune system and can be easily taken up by cells. Furthermore, they are
big enough to escape renal filtration, thus providing longer circulating half-life and
enhanced drug accumulation in tumor tissue [212].
No agglomeration was observed from TEM images indicating the effectivity of
PEGylated surface in prohibiting interaction between each of the CaP nanoparticles
as previously reported [210]. Since intravenous administration of nanoparticles prone
to aggregation was mentioned to result in the possibility of a pulmonary embolism,
strokes, myocardial infarctions, and other microinfarctions at distant sites and or-
gans [209], no agglomeration characteristics of Gd-DTPA/CaP nanoparticles is very
advantageous in reducing the possible toxicity problems.
The surface ξ-potential value of Gd-DTPA/CaP nanoparticles is also confirmed
to be around -0.5 mV, which is almost neutral and is preferable for drug delivery sys-
tem. Positively charged nanoparticles are known to interact with negatively charged,
phosphate-rich cell membrane and to be taken up in the reticuloendothelial system
(RES) [213]. Hence, slightly negative charged or neutral carriers are more desirable to
escape from the RES. Image of calcein-stained Gd-DTPA/CaP nanoparticles shown
in Fig. 6.5C demonstrates accumulation of nanoparticles on the surface and inside
the cancer cells, which proves the effectivity of CaP nanoparticles as carrier for Gd-
DTPA. With these characteristics of Gd-DTPA/CaP nanoparticles, we could expect
enhancement of gadolinium accumulation in tumor target.
6.3.2 Gadolinium Biodistribution
Gd-DTPA/CaP nanoparticles was previously proven to be capable of enhancing the
MRI image contrast compared to bare Gd-DTPA as shown in Fig 6.6. Free Gd-
DTPA was reported to be rapidly cleared from plasma and did not accumulate in
tumor tissue, and that only trace amounts of gadolinium (nearly 0.001% dose/ml)
were found in plasma 1 h after intravenous administration, while CaP nanoparticles
has been previously proven to be capable of extending Gd-DTPA blood circulation
time, which then increased gadolinium accumulation into tumor site [210].
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Figure 6.5: (A) TEM images of purified Gd-DTPA/CaP nanoparticles (B) Volume
averaged diameter distribution calculated from TEM images. (C) Calcein-stained
fluorescence images of Gd-DTPA/CaP nanoparticles accumulation on the surface and
into cells.
Figure 6.6: (A) MRI images of tumor-bearing mice after intravenous injection of Gd-
DTPA/CaP nanoparticles (tumor site is shown by dash circle area) (B) MRI images
of tumor-bearing mice after intravenous injection of bare Gd-DTPA. [210]
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Table 6.1: ICP-MS measurement results of gadolinium concentration at 12 and 24
hours after Gd-DTPA/CaP nanoparticles injection. Average data is presented ± the
uncertainty of ICP-MS.
Gd concentration (µg/g or mL)
12 hours 24 hours
Tumor 5.85 ± 0.64 8.03 ± 0.82
Blood 14.55 ± 0.50 3.29 ± 0.40
Liver 10.71 ± 0.17 16.71 ± 0.60
Spleen 7.08 ± 0.41 10.03 ± 0.30
Kidney 2.66 ± 0.24 2.13 ± 0.06
Brain 0.16 ± 0.01 0.04 ± 0.01
Quantitative analysis from ICP-MS measurement results of gadolinium accumula-
tion in tumor and several mice organs is shown in Table 6.1., where we could observe
tumor to blood (T/B) ratio of around 2.4 at 24 hours after Gd-DTPA/CaP nanopar-
ticles injection (Fig 6.7). This number is comparable to T/B ratio for BNCT, where
the optimum ratio that could be reached is considered to be around 3-4 [90]. Small
accumulation and fast clearance of gadolinium observed in brain samples is the evi-
dence of blood brain barrier existence in normal brain because of no modification in
Gd-DTPA/CaP nanoparticles for the disruption of blood brain barrier. Nevertheless,
the uptake of gadolinium by liver, kidney and spleen after compound injection was
still quite high, probably because of its characteristics that circulates in blood at first
and then distributes into the interstitial space or is eliminated by the kidneys in the
same manner with the results reported by [22] that major portion was discovered in
liver and spleen as the results of predominate renal elimination. Therefore, it is nec-
essary to ensure minimum neutron dose into organs other than tumor site to secure
tolerable irradiation effect on normal tissue. However, the ratio of gadolinium con-
centration in tumor to those in kidney was much smaller compared to our previous
result with gadoteridol-encapsulating liposome [84] (as shown in Table 6.2.), proving
the effectivity of Gd-DTPA/CaP nanoparticles in escaping renal filtration with its
small particle size.
Micro-distribution of Gd-DTPA/CaP in the tumors was previously reported from
the analysis by using micro-synchrotron radiation-induced X-ray fluorescence spec-
trometry (µ-SR-XRF), which is commonly used to visualize element distribution in
tumor slice. Higher intensity of Ca and Gd was found in tumor slices injected with
68
Figure 6.7: (A) Gadolinium accumulation in blood plasma. (B) Gadolinium concen-
tration in tumor site. (C) Tumor to blood ratio of gadolinium concentration. Data
shown is the average measurement with error bar indicating variance of measured
data.
Table 6.2: Gadolinium concentration ratio between tumor to several mice vital organs
for mice injected with Gd-DTPA/CaP nanoparticles compared to Gd-Liposome from
previous work [84].
Gd concentration ratio
Gd-DTPA/CaP Gd-Liposome
Liver 1. 9 1.34
Spleen 1.13 6.18
Kidney 1.5 14
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Figure 6.8: Micro-distributions of Gd-DTPA/CaP and Gd-DTPA in tumor sections
scanned by µ-SR-XRF. (A)H&E staining of tumor section and Gd, Fe and Ca elements
distributions in tumor slice 4 hours after intravenous injection of Gd-DTPA/CaP
nanoparticles. (B) H&E staining of tumor section and Gd, Fe and Ca elements
distributions in tumor slice 4 hours after intravenous injection of bare Gd-DTPA.
[210]
Gd-DTPA/CaP compared to that of bare Gd-DTPA, indicating enhanced accumu-
lation by Gd-DTPA/CaP. Moreover, the presence of the Gd and Ca atoms for Gd-
DTPA/CaP was homogeneous and accumulating around and distant from the Fe-rich
areas of blood vessels, suggesting effective blood circulation as well as tumor pene-
tration of the Gd-DTPA/CaP nanoparticles as shown in Fig. 6.8 [210].
Higher gadolinium accumulation in tumor site was also successfully achieved for
multiple injections of Gd-DTPA/CaP nanoparticles as shown in Fig. 6.9A, where
gadolinium concentration reached the amount of more than three times higher com-
pared to those at 10 hours after the first injection. Significant increase of gadolinium
concentration in blood plasma was also observed at 30 hours after the first injec-
tion (Fig. 6.9B). This indicates the prolonged blood circulation of Gd-DTPA/CaP
nanoparticles, which is important because with repeated passages of the delivery sys-
tem through the tumor microvascular bed, a greater efficiency of extravasations per
unit volume of the transports could be achieved.
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Figure 6.9: ICP-MS results for multiple injections of Gd-DTPA/CaP nanoparticles
compared to bare Gd-DTPA: (A) Gadolinium concentration in tumor tissue (B)
Gadolinium accumulation in blood plasma. Data shown is the average gadolinium
concentration with error bar indicating the variance of measurement.
Table 6.3: Average physical dose from the measurement during neutron irradiation
Physical dose (Gy)
Thermal neutron (∼0.5eV) 2.4 × 10−1
Epithermal neutron (0.5eV∼10keV) 2.45 × 10−2
Fast neutron (10keV∼) 1.8 × 10−1
Gamma ray 4.7 × 10−1
Total 9.1 × 10−1
Natural gadolinium (1ppm) 2.4 × 10−3
Gadolinium-157 (1ppm) 1.25 × 10−2
6.3.3 Neutron Irradiation
During the 60 minutes of neutron irradiation, average neutron fluence was measured
to be 1.8 × 1012 n/cm2 for thermal neutron range and 3.2 × 1011 n/cm2 for epithermal
neutron, while physical dose from neutron and gamma ray measurement results on
the surface of mice irradiation plate are shown in Table 6.3. It is defined that thermal
neutron region is below 0.5 keV, the epithermal neutron region is 0.5 keV-10 keV and
the fast neutron region is over 10 keV. These results are also comparable to physical
dose meausured in the GdNCT experiment performed by other researchers at the
same reactor facility in KUR [187].
Even though the measured physical dose for 157Gd was lower compared to the dose
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contribution from other components, the limitation of this value needs to be taken
into account since a more pertinent equivalent dose calculation is necessary to express
cancer cells killing effect after GdNCT treatment, where the Auger and Coster-Kronig
electron might contribute significant biological effect in killing the cancer cells. Among
GdNCR products, Auger electrons are the most biologically relevant to be comparable
with high LET alpha particle and lithium ions from BNCR. They have energy range
between 0 and 50 keV with an average of 4.19 keV [134], with corresponding average
LET of 0.3 MeV/mm. By comparison, the average LET in BNCR is 0.2 MeV/mm
for both lithium and alpha particles [4]. Contribution of Auger electrons to high-
resolution neutron radiographs with gadolinium converter plate was already reported
by [214], providing the evidence for the existence of Auger electrons during GdNCR.
The presence of Auger electrons after GdNCR has also been proven with the range
of no more than 2.7 mg/cm2 [26]. Yasui and co-workers [87] have also reported the
effectivity of gadolinium neutron capture therapy in vitro on glioblastoma multiforme
cells, where they observed significant enhancement of cell killing on cells preloaded
with Gd-DTPA and treated with neutron irradiation. Following observation of no
necrosis with high cancer cells killing effectivity after GdNCT was reported in their
experiment compared to other mice group treated with gamma, fast neutrons, and
modified enhanced thermal neutron beam [88]. They mentioned the discovery of
extreme autophagy in GdNCT treated group might provide the clues in understanding
how Auger electron irradiation kills the cancer cells. These short-range products may
enhance the therapeutic effects of gadolinium neutron capture therapy (GdNCT) and
are expected to deliver high cell killing effect when incorporated into DNA [215], and
with proper techniques, GdNCT might be made competitive to BNCT.
6.3.4 Evaluation of Antitumor Effectivity
In this experiment, we performed neutron irradiation on single-injected and multiple-
injected nanoparticles to compare the cancer cells killing effectivity after GdNCT
treatment. Effectivity of tumor growth suppression after NCT treatment for single
injection group is shown in Fig 6.10. It is evident that the tumor growth of GdNCT
treated group was suppressed more than three times higher compared to the non-
treated group, suggesting the effectivity of GdNCT treatment. Morphological results
shown in Fig 6.11 also reveals suppressed tumor volume on Gd-DTPA/CaP injected
irradiated group compared to the non-irradiated and non-treated group.
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Figure 6.10: Tumor growth suppression after neutron irradiation for single-injected
Gd-DTPA/CaP nanoparticles compared to non-injected group. Data shown is average
tumor volume growth from 4-5 mice on each group with error bar indicating variance
of measurement.
Figure 6.11: Representation of tumor-bearing mice showing the comparison of mor-
phological observation between irradiated and non-irradiated on single injection for
both Gd-DTPA/CaP nanoparticles and bare Gd-DTPA.
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Tumor volume growth by time for multiple-injected group is shown in Fig 6.12,
where we could observe that Gd-DTPA/CaP irradiated group revealed up to more
than four times tumor growth suppression compared to non-treated group. However,
the multiple-injected mice group did not reveal better tumor growth suppression even
though gadolinium concentration accumulated in tumor site is much higher compared
to the single-injected mice group as shown previously in Fig 6.10. There is a possibility
that neutron depression occurred in this group where neutron were being absorbed
and could not reach deeper site of the tumor, which might reduce the effectivity of
cancer cells killing. Nevertheless, we could still observe tumor growth suppression
after neutron irradiation, which suggests the possibility of cancer cells killing from
secondary particles of GdNCR. No significant weight loss was observed after neutron
irradiation and all mice survived until the end of observation, suggesting low toxicity
of Gd-DTPA/CaP nanoparticles for GdNCT (Fig 6.13).
The low toxicity of Gd-DTPA/CaP nanoparticles is also supported by the results
shown in Fig 6.14, where we observed mice dead in the group with multiple injec-
tions of bare Gd-DTPA, both fpor non-irradiated and non-irradiated group. This
result indicates that the dose for three times injection of Gd-DTPA might already
surpass the tolerable dose of gadolinium toxicity for tumor-bearing mice. However,
encapsulating Gd-DTPA into calcium phosphate-based nanoparticles as carried out
in current experiment, has lower the toxicity effect.
The therapeutic effects of GdNCT were also observed from pathological analysis
results of tumor cells as shown by H&E staining results in Fig 6.15. Nucleus and cyto-
plasm of tumor cells treated with Gd-DTPA/CaP nanoparticles were destroyed after
GdNCT treatment (cells inside the dash area), while the non-irradiated group showed
normal histology with survived nuclei and abundant cytoplasm, demonstrating the
characteristics of proliferative tumor cells. Similar H&E result was observed between
single-injected and multiple-injected group, which agrees with the results from tu-
mor growth suppression effect. This is also supported by TUNEL assay shown in
Fig 6.16, where the number of cells undergoing stained by TUNEL, which correlates
to the number of apoptosis, was higher on GdNCT treated group compared to the
non-irradiated ones.
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Figure 6.12: Tumor growth suppression for multiple-injected Gd-DTPA/CaP
nanoparticles compared to single-injected mice for both irradiated and non-irradiated
group. Data shown is average tumor volume growth from 4-5 mice on each group with
error bar indicating variance of measured tumor volume.
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Figure 6.13: Graph of mice weight loss for single and multiple injections of Gd-
DTPA/CaP nanoparticles after neutron irradiation compared to the non-irradiated
group. Data shown is average mice weight from 4-5 mice on each group with error
bar indicating variance of measured data.
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Figure 6.14: Comparison of tumor growth suppression between multiple injections
of bare Gd-DTPA to control (non-injected) group. (*) mark indicates mice dead
observed on multiple injected mice on both irradiated and non-irradiated group. Data
shown is average tumor volume growth from 4-5 mice on each group with error bar
indicating variance of measurement.
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Gd-DTPA/CaP single injection + Irradiation 
Gd-DTPA/CaP single injection
Gd-DTPA/CaP multiple injections + Irradiation 
Gd-DTPA/CaP multiple injections
Figure 6.15: Comparison of H&E staining results for single injection and multiple
injections of Gd-DTPA/CaP nanoparticles, both for irradiated and non-irradiated
mouse.
Gd-DTPA/CaP single injection + Irradiation Gd-DTPA/CaP multiple injections + Irradiation 
Gd-DTPA/CaP single injection Gd-DTPA/CaP multiple injections
Figure 6.16: Comparison of TUNEL staining results for single injection and multiple
injections of Gd-DTPA/CaP nanoparticles, both for irradiated and non-irradiated
mouse.
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Chapter 7
Preliminary Dosimetry of BNCT and
GdNCT
7.1 Introduction
NCT is simple in theory but in reality demands a high technical quality of the involved
dose contributing components. The physical parameters involved are well known
but interact in a rather complex way. One factor that is necessary to consider is
the production and delivery of the applied external neutron field. Thermal neutrons
cannot be used directly to irradiate deeply sited target volumes since they are strongly
attenuated in the tissue and more appropriate for surface tumor. Due to their better
penetration, epithermal neutrons have instead been employed for neutron source in
NCT as previously discussed in the neutron source subsection.
Energy release resulting from interactions of neutrons with the nuclei of a sub-
stance is usually divided into local energy release from neutron reactions, and energy
release from absorption of secondary photons originating as a result of these reactions.
Therefore, calculation of the absorbed dose in a target organ is determined by the
sum of the doses of neutrons and secondary gamma, and the dose of primary photons
of the beam [133]. Optimization of the treatment required calculation of the dose
distribution at various parameter combinations to maximize the radiation dose to the
target volume, while keeping the dose to normal tissues within the limits prescribed
in the protocol.
As described formerly in Chapter 2, dosimetry and treatment planning system
for NCT has been through extensive development especially on integrated system
between NCT agent detection and dosimetry calculation for an optimized treatment
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planning system. Monte Carlo method is said to be the most accurate and rigorous
absorbed dose calculation method to simulate radiation transport and scoring energy
deposition in heterogeneous systems such as the human body. The Monte Carlo
method can accurately account for variations in density and atomic number and can
handle complex geometry [216].
7.2 Materials and Methods
7.2.1 Particle and Heavy Ion Transport code System (PHITS)
We carried out dose calculation by using Particle and Heavy-Ion Transport code
System (PHITS), which is a multi-purpose particle Monte Carlo transport code that
has been developed under the collaboration of JAEA (Japan Atomic Energy Agency),
RIST (Research Organization for Information Science and Technology), KEK (High
Energy Accelerator Research Organization) and Chalmers University of Technology.
PHITS is a multi-purpose particle Monte Carlo transport code, which can deal with
the transport of all particles (nucleons, nuclei, mesons, photons, and electrons) over
wide energy ranges, using several nuclear reaction models and nuclear data libraries.
Various quantities such as heat deposition, track length and production yields can be
deduced from the simulation, using implemented estimator functions called ”tally”.
The code also has a function to draw 2D and 3D figures of the calculated results as
well as the setup geometries, using a code ANGEL. Because of these features, PHITS
has been widely used for various purposes such as designs of accelerator shielding,
radiation therapy and space exploration [217].
In PHITS, neutrons can be transported from thermal energies up to 200 GeV.
Below 20 MeV down to 0.1 meV, neutrons are described in the same manner as in
the MCNP4C code based on the Evaluated Nuclear Data such as the ENDF-B/VI,
JENDL-3.3, and LA150 libraries. For charged particles except for nuclei below 1
MeV, only the ionization process is considered until the charged particles are stopped.
PHITS also uses Evaluated Nuclear Data for photon and electron transport in the
same manner as in the MCNP4C code based on ITS version 3.0 code. The energy
range of electron and photon was restricted to the energy region 1 keV - 1 GeV, but
the extension of the maximum energy of these particles has been done recently by
including the EGS5 code [218].
PHITS provides a variety of tallies, which score track length, flux and current
of crossing surface, produced particle and residual nucleus at the collision, average
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heat and distribution of deposit energy, star density, and DPA (displacements per
atom). These quantities can be tallied in a cell defined by the geometry and also
by the super-imposed r-z and xyz scoring meshes [218]. PHITS is also mentioned to
be capable of generating multiple particles in source definition concurrently, though
MCNP generates only one particle. Thus, we can make a proper beam source includ-
ing both neutrons and photons at the patient position; then doses involving primary
core gamma-ray dose can be evaluated effectively [219].
For the dose calculation, we used [T-Heat] tally feature in PHITS, which is men-
tioned to give deposit energy for optional region and deposit energy by low energy
neutron, photon, and electron. By using this tally, the heat from neutrons and pho-
tons are usually obtained from Kerma factor with nuclear data. Simulation of dose
distribution in this study was performed as an early stage of investigating dose contri-
bution from various ionizing radiations including: neutron beam from nuclear reactor,
gamma contamination of the neutron beam, and contribution from secondary particle
produced after neutron capture reaction.
7.2.2 Simple Mouse Phantom
In this study, we designed a simple mouse phantom and performed dose calculation
of neutron and gamma beam separately from the secondary particle produced after
neutron capture reaction. The phantom was relatively simplistic and only consider
several vital organs in which we have measured the accumulation of gadolinium dur-
ing previous in vivo experiment and boron concentration was chosen as the minimum
amount based on several clinical reports. Extreme boron and gadolinium concentra-
tion of 1000 ppm was also considered in the calculation to evaluate the possibility of
neutron depression, even though it might be difficult to achieve in real application.
Geometry of the mouse phantom is shown in Fig. 7.1. Each identified organ,
tissue, or structure in the phantom was assigned a tissue composition, taken from
their human counterparts published in ICRU Report 46 (ICRU 46). The bulk of the
remainder of the mouse was described as adipose tissue. Table 7.1 shows all of mice
organs considered in current study along with their tissue compositions.
7.2.3 Cylindrical Phantom
We also performed calculation of heat deposition on a cylindrical phantom with radius
of 10 cm and height 10 cm divided into 10 identical cells. Neutron beam was set to be
incident directly to the cylindrical phantom’s surface perpendicular to the cylinder’s
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Figure 7.1: Simple geometry of mouse phantom constructed using PHITS.
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Table 7.1: List of organs and tissue composition designation
Structure name Composition designation
Lungs ICRU 46 Lung Adult (healthy) inflated
Heart ICRU 46 Heart Adult (healthy)
Kidney ICRU 46 Kidney Adult
Liver ICRU 46 Liver Adult (healthy)
Spleen ICRU 46 Spleen Adult
Tumor ICRU 46 GI tract Adult
Bulk of the remainder ICRU 46 Adipose Tissue
base. Colon tissue material is assigned for the phantom by taking into account that
the cancer cells in previous experiment is colon-26 cell line.
The main objective of the calculation with this cylindrical phantom is to eval-
uate the tendency of dose deposition by depth from neutron beam as well as the
possibility of neutron depression effect when boron and gadolinium concentration is
significantly higher compared to those commonly achieved for clinical trial or in vivo
experiment. Calculation of heat deposition for comparison as well as investigation
of possible combined effect between boron and gadolinium was also performed with
various concentration from 20 ppm, 40 ppm and 1000 ppm compared to the heat
deposition when the cylinder is filled with equally 40 ppm of boron combined with
gadolinium.
7.2.4 Calculation Setup
Dose calculation performed in this study is still a preliminary investigation of NCT
dose deposition with the experiment conditions for collimated neutron irradiation
described in Chapter 5 and 6. This preliminary dose calculation was aimed to ana-
lyze dose deposition for collimated neutron irradiation in HWNIF of KURRI. In our
experiment, neutron irradiation was carried out with OO-0000-F operation mode, a
mixed neutron beam where the major neutron energy range is thermal neutron fol-
lowed by epithermal and fast neutron. This operation mode is commonly used for
clinical trials in treating patients and animal experiment at KUR.
Not all the geometry condition will be included in the calculation parameter since
the spectrum of neutron and gamma from the nuclear reactor (as described in Chap-
ter 4) obtained was already described as calculated from the exit of the irradiation
window. The source was mentioned to be a mono-directional disc source with the
radius of 12.5 cm with the energy spectrum for each neutron and photon as described
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LiF collimator
Figure 7.2: LiF shielding set-up for collimated neutron irradiation experiment.
in Chapter 4. Shielding plate made of LiF was designed to shield neutron irradiation
from exposing other organs of tumor-bearing mice. Referring to the experimental set-
up given in Fig. 7.2, we constructed PHITS geometry input for the LiF collimator
with a circle opening in front of the tumor site as shown in Fig. 7.3.
7.3 Results and Discussions
7.3.1 Simple Mouse Phantom
Dose calculation result of deposited heat from PHITS calculation is given in Fig. 7.4.
By looking at the dose distribution in mouse organs for both boron and gadolinium,
we could observe higher heat deposition in tumor site on GdNCT compared to those
in BNCT, possibly coming from the higher neutron cross section of gadolinium, which
produces higher number of neutron capture reaction. The high heat deposition ob-
served on LiF shielding proves its neutron absorbing effect with the largest volume
compared to other cells in the calculation.
Heat deposition on tumor site for both BNCT and GdNCT is also shown to be
higher compared to other mice organs indicating the effect of neutron capture reaction
by such neutron absorber compound considering that the percentage of boron or
gadolinium in tumor is much lower compared to the other elements composing the
other organs. Similar shape was also observed on the heat deposition into other
mice organs (excluding LiF shield and tumor site) for both calculation on boron and
gadolinium when compared between those containing 40 ppm and 1000 ppm.
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Figure 7.3: Simple geometry of mouse phantom constructed by using PHITS code.
For the upper image, neutron source from the reactor is coming towards the paper di-
rection, as for the lower image, neutron source is coming upward toward the phantom
from the horizontal axis.
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Figure 7.4: Calculated heat deposition for each region of mice organ including the LiF
shielding for: (A) Boron concentration of 1000 ppm, (B) Gadolinium concentration
of 1000 ppm, (C) Boron concentration of 40 ppm, (D) Gadolinium concentration of
40 ppm.
86
7.3.2 Cylindrical Phantom
The results of calculated neutron flux for cylindrical phantom with gadolinium con-
centration of 1000 ppm is given in Fig. 7.5, where we can see that it was reduced
siginificantly after the second cell on the depth of 2 cm from the cylinder’s surface.
There could be a possibility of higher neutron depression for gadolinium from the ob-
servation of its higher decrease rate in heat deposition for both concentration being
considered in the calculation as shown in n Fig. 7.6, even though the ratio is not
linear compared to its ratio of neutron cross section when compared to boron.
Heat deposition tendency of boron are both similar for the concentration of 40 ppm
and 1000 ppm, while it was decreased siginificantly on the second cell (2 cm depth
from the cylinder’s surface) for the 1000 concentration of gadolinium, suggesting the
possibility of neutron depression effect, which might be caused by higher neutron
cross section of gadolinium. Even though gadolinium neutron cross section is more
than 60 times higher compared to boron-10 isotope, heat deposition on gadolinium
was observed to be around 3 times higher compared to those deposited on the heat
calculation with boron. This is comparable with the calculation previously reported
by Goorley [77], in consideration that with the higher mass number of gadolinium,
the same concentration of both compound translate into lower number of atom of
gadolinium compared to boron.
However, it is necessary to point out that the ratio of heat deposition between
gadolinium and boron from the calculation results results was observed to be increas-
ing at the depth of 8 cm forward from the cylinder surface, suggesting the possibility
of superior cells killing effect of gadolinium for deeper tumor site considering that its
neutron cross section at are higher on higher neutron energy range as well compared
to boron. This characteristics would also be advantageous for accelerator-based neu-
tron source where the produced neutron spectrum are usually harder compared to
those from nuclear reactor. Nevertheless, we can not come into conclusion yet before
performing further advanced calculation especially the necessary to perform micro-
dosimetry of dose deposition from very short range secondary particles such as Auger
and Coster-Kronig electrons produced after GdNCR.
7.3.3 Evaluation on Possible Combined Effect of BNCT and
GdNCT
To evaluate the possibility of combining boron and gadolinium as NCT agent, we
performed calculation of heat deposition with various concentration from 20 ppm,
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Figure 7.5: Calculated neutron flux for cylindrical phantom with gadolinium concen-
tration of 1000 ppm.
40 ppm and 1000 ppm compared to the heat deposition when the cylinder is filled
with equally 40 ppm of boron and gadolinium. From the results shown in Fig. 7.7,
we can see that higher additional effect was achieved on the combination of 40 ppm
boron with 1000 gadolinium, compared to the 40 ppm of gadolinium and 1000 boron.
However, the calculation results in this study are still a preliminary investigation in-
tended for further calculation. The heat deposition was calculated for total ionization
effect of all secondary particles after neutron capture reaction and did not present
the contribution from each ionizing radiation.
However, the depression effect on the second cell of cylinder was observed on 1000
ppm of gadolinium, indicating that combination with higher boron concentration
could be a better choice for the treatment of surface tumor. Nevertheless, the ratio
of 40 ppm boron + 1000 ppm Gd to the 40 ppm gadolinium + 1000 ppm boron,
is increasing up to 3 times higher from 8th cell onward, indicating that combination
with higher boron concentration might be preferable to treat deep-seated tumor. This
result might come from the contribution of deeper penetration of epithermal neutron
in the neutron beam which was still captured by gadolinium with its high neutron
cross section, not only on the thermal neutron energy range.
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Figure 7.6: Comparison of heat deposition for 40 ppm and 1000 ppm concentration
of each boron and gadolinium
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On top of that, dose contribution of GdNCR short-range products such as Auger
electron emission has often been neglected because it was assumed that Gd compounds
remained extracellular and could not reach the cell nucleus. However, De Stasio et
al., [76] has shown that Gd-DTPA not only penetrates the plasma membrane of the
cells but accumulates at higher concentration in the nucleus than in the cytoplasm.
Therefore, it is recommended to take into account as well the dose contribution from
Auger and internal conversion electrons in the calculation for future investigation.
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Figure 7.7: Comparison of heat deposition for 40 ppm and 1000 ppm concentration
of each boron and gadolinium
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Chapter 8
Closing Remarks
This thesis has considered two types of gadolinium-based drug compounds to be
evaluated as GdNCT agent by performing in vivo experiment on colon-26-bearing-
mice, irradiated by neutron source at HWNIF of KURRI in Kumatori, Osaka. Dose
calculation has also been performed as an independent approach to investigate heat
deposition from dose contributing elements of nuclear reactor beam along with the
secondary particle produced after neutron capture reaction for both GdNCT as well
as BNCT.
8.1 General Conclusion
In Chapter 5 we have presented the results of in vivo experiment as continued eval-
uation of Gd-DTPA/DACHPt-loaded nanomicelles for NCT agent. We have shown
that gadolinium accumulation is more effective compared to bare Gd-DTPA from
the observation of MRI contrast enhancement and ICP-MS measurement. Previ-
ous experiment at KURRI with neutron collimator, various neutron fluences, in-
cluding neutron-shielded condition, still showed quite high toxicity of gadolinium-
platinum nanomicelles on irradiated tumor-bearing mice. On this experiment with
various neutron fluences, we observed significant prolongation of survival rate for
Gd-DTPA/DACHPt-loaded nanomicelles-injected group irradiated for 17.5 minutes
(1× 1012 n/cm2 neutron fluence). Even though only 60% survived until 27 days after
neutron irradiation, this result shown that irradiation time affect deposited dose quite
significantly into mouse organs that might cause mouse death.
Continued experiment of neutron irradiation on mice injected with Gd-DTPA/DACHPt-
loaded micelles and DACHPt micelles only, have revealed that even with current
experimental procedure, high toxicity was still observed on all irradiated mice for
92
both group. We have performed neutron irradiation on 12 hours and 24 hours af-
ter compound injection considering different platinum amount in blood plasma at
those times. However, we still observed severe toxicity, which caused death to all
irradiated mice of both Gd-DTPA/DACHPt-loaded micelles and DACHPt micelles
only injected group. Our speculation is that there is a possibility of platinum pho-
toactivation, caused by reaction between secondary particles produced after GdNCR
such as gamma rays and characteristics X-ray with energy above K-edge energy of
platinum, which might increase drug toxicity and induced ionizing radiation at vital
organs. Moreover, as the nanomicelles compound bind gadolinium and platinum to-
gether very close, the possibility of secondary reaction to occur is higher since the
effective solid angle is very large. Even though we could observe tumor growth sup-
pression compared to the non-irradiated group, the high toxicity results suggested
that the feasibility of combined radiochemotherapy for Gd-Pt nanomicelles is diffi-
cult to achieve within tolerable toxicity with current experimental setup of injected
dose and neutron irradiation dose.
In Chapter 6, we have shown that Gd-DTPA/CaP nanoparticles significantly en-
hanced gadolinium accumulation compared to those of free Gd-DTPA proven from the
results of previously reported MRI image along with the ICP-MS measurement, where
the gadolinium concentration in tumor site is significantly higher for Gd-DTPA/CaP
nanoparticles. Several experimental setups were performed for mice group injected
with this compound and the results have demonstrated the possible effectivity of it as
GdNCT agent. Tumor growth suppression was obtained up to more than four times
higher compared to the non-treated group for a single injection of Gd-DTPA/CaP
nanoparticles, supported by the morphological and histopathological results after neu-
tron irradiation. H&E staining results indicated that nucleus and cytoplasm of the
tumor cells were destroyed after GdNCT treatment, which agrees with the results
of TUNEL staining, where the number of cells undergoing stained by TUNEL that
correlates to the number of apoptosis, was higher on GdNCT treated group compared
to the non-irradiated ones.
It has also been shown that Gd-DTPA/CaP nanoparticles accumulate gadolinium
in tumor site more effectively after comparing the results of our previous work on
gadolinium-entrapping liposome. Gd-DTPA/CaP nanoparticles’ smaller particle size
is proven to be capable of accumulating gadolinium in higher percentage from initial
injected dose. This smaller size has also been proven to be efficient in escaping
the renal filtration demonstrated by the ratio of gadolinium concentration in tumor
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to kidney, which is significantly lower in Gd-DTPA/CaP nanoparticles compared to
those in gadolinium-entrapped liposome from our previous work.
Higher gadolinium accumulation in tumor site was also successfully achieved for
multiple injections of Gd-DTPA/CaP nanoparticles as well as significant increase
of gadolinium concentration in blood plasma at 30 hours after the first injection.
This indicates prolonged blood circulation of Gd-DTPA/CaP nanoparticles, which is
important in optimization of drug delivery. However, the multiple-injected mice group
did not reveal better tumor growth suppression even though gadolinium concentration
accumulated in tumor site is much higher compared to the single-injected mice group.
There is a possibility that neutron depression occurred in this group where neutron
were being absorbed and could not reach deeper site of the tumor, which might reduce
the effectivity of cancer cells killing. Nevertheless, we could still observe tumor growth
suppression after neutron irradiation, which suggests the possibility of cancer cells
killing from secondary particles of GdNCR.
Low toxicity of Gd-DTPA/CaP nanoparticles has also been proven from the ob-
servation of no significant mice weight loss during 27 days after neutron irradiation,
which is also supported by the results on multiple-injected group, where we observed
mice dead on multiple injections of bare Gd-DTPA while all mice injected with Gd-
DTPA/CaP nanoparticles survived until the end of observation. These results let us
come into conclusion that Gd-DTPA/CaP nanoparticles could be a promising delivery
device for GdNCT.
Preliminary investigation of dose deposition in Chapter 7 was intended to be an
early stage of independent approach before going into real calculation of dose depo-
sition from all possible contributing elements in BNCT and GdNCT dose deposition.
The calculation was designed by referring to the experimental condition of neutron ir-
radiation for gadolinium-based compounds-injected group. Dose calculation approach
performed in this study was performed on a simple mouse phantom designed based on
the tumor-bearing mice irradiated at KUR along with a simple cylindrical phantom
with the materials of GI tract tissue to represent colon cancer cells. For the cal-
culation results on simple mouse phantom, higher heat deposition in tumor site was
observed for GdNCT compared to those in BNCT, which might come from the higher
neutron cross section of gadolinium. Heat deposition on tumor site for both BNCT
and GdNCT is also shown to be higher compared to other mice organs indicating the
effect of neutron capture reaction by such neutron absorber compound considering
that the percentage of boron or gadolinium in tumor is much lower compared to the
other elements composing the other organs.
94
As for the cylindrical phantom dose calculation, the possibility of higher neu-
tron depression was indeed observed for gadolinium compound compared to that
introduced to boron, demonstrating the higher capability of gadolinium in capturing
thermal neutron. And for the calculation for combined effect of boron and gadolin-
ium, we can see that higher additional effect was achieved on the combination of 40
ppm boron with 1000 gadolinium, compared to the 40 ppm of gadolinium and 1000
boron. Nevertheless, since the result of dose calculation in current study is still a pre-
liminary investigation, we can not come into conclusion yet before performing further
advanced calculation especially the necessary to perform microdosimetry of dose de-
position from very short range secondary particles such as Auger and Coster-Kronig
electrons produced after GdNCR.
8.2 Limitations and Suggestions
Quite severe toxicity observed in irradiated mice injected with Gd-DTPA/DACHPt-
loaded nanomicelles, even with various experimental setup performed in the above-
mentioned evaluation indeed indicated the difficulty of this nanoparticles application
in GdNCT. However, there might still be a possibility to evaluate toxicity effect by
performing irradiation with only gamma-rays beam on tumor-bearing mice injected
with Gd-DTPA/DACHPt-loaded nanomicelles, which is not yet carried out in cur-
rent work. Similar procedure with two separate groups of Gd-DTPA/DACHPt-loaded
nanomicelles and DACHPt nanomicelles only to confirm whether the toxicity effect
is caused by the reaction between gadolinium or platinum with neutron or gamma
only. Since platinum-based chemotherapy agent itself (such as oxaliplatin used in this
work) has been previously reported to be capable of enhancing the cytotoxic effect
when combined with high LET radiation (as summarized previously in Chapter 3).
Considering that current investigation of Gd-DTPA/CaP nanoparticles were per-
formed on tumor-bearing mice by injecting cancer cells line subcutaneously, it is
demonstrated effective tumor growth suppression for surface-tumor after GdNCT
treatment. Further investigation on GdNCT feasibility for deep-seated tumor and
detail analysis on tumor-to-skin dose ratio could be few of the parameters that could
optimize GdNCT treatment for better cancer cells-killing enhancement.
The assumption of neutron depression effect on the experiment with multiple in-
jections of Gd-DTPA/CaP nanoparticles group cannot yet be concluded from current
results because there is also the possibility of inhomogeneous distribution of Gd-
DTPA/CaP nanoparticles in the tumor site that the cancer cells killing effect is not
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uniform. It would be recommended to perform histological analysis on several slice of
the tumor sample on different site covering the surface part which is the closest to the
neutron beam, the middle and the deepest part of tumor which are the furthest from
neutron incident. It is expected that evaluation on the cancer cells killing effect on
different position of tumor slice would give a better understanding on the effectivity
of GdNCT.
Dosimetry calculation performed in this work is still limited to the estimation
of NCT heat deposition from the kerma conversion factor included in PHITS. It
would be recommended to conduct an advanced dose calculation study to investigate
detail dosimetry including macrodosimetry and microdosimetry calculation from all
possible contributing elements of ionizing radiation for optimization of both BNCT
and GdNCT, especially the microdosimetry for ionization effect from the very short
range secondary particles of GdNCR to investigate the possibility of their additional
cancer cells killing effect. The same case applies for the evaluation of combination
effect between BNCT and GdNCT.
A well-developed hospital-based of accelerator-based neutron source in near future
would be more practical and patient-friendly for NCT application, which will eventu-
ally bring the possibility of its clinical approval. Developing an established detection
system, especially in intercellular level for a more precise estimation of dosimetry.
Investigation on the possible combination between boron and gadolinium in NCT
or combination of NCT with other types of radiation therapy (e.g. proton therapy,
brachytherapy and synovectomy) would be more beneficial instead of exploiting each
of them as a single treatment. Interdisciplinary exchange between scientific commu-
nities along with an easy to understand socialization also plays a great role in order
to obtain public acceptance for the advancement of NCT in the future.
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